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Abstract
The transcriptome is the entire set of transcripts that are expressed from the genes of an organism under
some conditions and at a particular time. The transcriptome can be sequenced into reads in order to find
clues about genes and protein sequences, structures, and their functions. While in the past, transcriptome
sequencing technology used to be costly and slow, more recently, next generation sequencing technology
has emerged, decreasing the cost and increasing the speed of genome, transcriptome and exome sequencing.
However, raw sequences come with artifacts, and hence preprocessing the reads is required for downstream
analysis. In this dissertation, we have proven that preprocessing sequencing data is required for better
performance throughout the genomics processing.
In addition, we propose many machine learning models that serve as contributions to solve a biolog-
ical problem. First, we present Zseq, a linear time method that identifies the most informative genomic
sequences and reduces the number of biased sequences, sequence duplications, and ambiguous nucleotides.
Zseq finds the complexity of the sequences by counting the number of unique k-mers in each sequence as
its corresponding score and also takes into the account other factors, such as ambiguous nucleotides or high
GC-content percentage in k-mers. Based on a z-score threshold, Zseq sweeps through the sequences again
and filters those with a z-score less than the user-defined threshold. Zseq is able to provide a better mapping
rate; it reduces the number of ambiguous bases significantly in comparison with other methods. Evaluation
of the filtered reads has been conducted by aligning the reads and assembling the transcripts using the ref-
erence genome as well as de novo assembly. The assembled transcripts show a better discriminative ability
to separate cancer and normal samples in comparison with another state-of-the-art method.
Studying the abundance of select mRNA species throughout prostate cancer progression may provide
some insight into the molecular mechanisms that advance the disease. In the second contribution of this
dissertation, we reveal that the combination of proper clustering, distance function and Index validation
for clusters are suitable in identifying outlier transcripts, which show different trending than the majority
of the transcripts, the trending of the transcript is the abundance throughout different stages of prostate
cancer. We compare this model with standard hierarchical time-series clustering method based on Euclidean
distance.
Using time-series profile hierarchical clustering methods, we identified stage-specific mRNA species
termed outlier transcripts that exhibit unique trending patterns as compared to most other transcripts
during disease progression. This method is able to identify those outliers rather than finding patterns among
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the trending transcripts compared to the hierarchical clustering method based on Euclidean distance. A
wet-lab experiment on a biomarker (CAM2G gene) confirmed the result of the computational model. Genes
related to these outlier transcripts were found to be strongly associated with cancer, and in particular,
prostate cancer. Further investigation of these outlier transcripts in prostate cancer may identify them as
potential stage-specific biomarkers that can predict the progression of the disease.
Breast cancer, on the other hand, is a widespread type of cancer in females and accounts for a lot of
cancer cases and deaths in the world. Identifying the subtype of breast cancer plays a crucial role in selecting
the best treatment. In the third contribution, we propose an optimized hierarchical classification model that
is used to predict the breast cancer subtype. Suitable filter feature selection methods and new hybrid feature
selection methods are utilized to find discriminative genes. Our proposed model achieves 100% accuracy for
predicting the breast cancer subtypes using the same or even fewer genes.
Studying breast cancer survivability among different patients who received various treatments may help
understand the relationship between the survivability and treatment therapy based on gene expression. In
the fourth contribution, we have built a classifier system that predicts whether a given breast cancer patient
who underwent some form of treatment, which is either hormone therapy, radiotherapy, or surgery will
survive beyond five years after the treatment therapy. Our classifier is a tree-based hierarchical approach
that partitions breast cancer patients based on survivability classes; each node in the tree is associated with
a treatment therapy and finds a predictive subset of genes that can best predict whether a given patient
will survive after that particular treatment. We applied our tree-based method to a gene expression dataset
that consists of 347 treated breast cancer patients and identified potential biomarker subsets with prediction
accuracies ranging from 80.9% to 100%. We have further investigated the roles of many biomarkers through
the literature.
Studying gene expression through various time intervals of breast cancer survival may provide insights
into the recovery of the patients. Discovery of gene indicators can be a crucial step in predicting survivability
and handling of breast cancer patients. In the fifth contribution, we propose a hierarchical clustering method
to separate dissimilar groups of genes in time-series data as outliers. These isolated outliers, genes that trend
differently from other genes, can serve as potential biomarkers of breast cancer survivability.
In the last contribution, we introduce a method that uses machine learning techniques to identify tran-
scripts that correlate with prostate cancer development and progression. We have isolated transcripts that
have the potential to serve as prognostic indicators and may have significant value in guiding treatment
decisions. Our study also supports PTGFR, NREP, scaRNA22, DOCK9, FLVCR2, IK2F3, USP13, and
CLASP1 as potential biomarkers to predict prostate cancer progression, especially between stage II and
subsequent stages of the disease.
viii
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Chapter 1
Introduction
1.1 Transcriptome
Molecular biology is a branch of biochemistry that studies the molecular basis of biological
activity among biomolecules in a cell, such as the synthesis of DNA to RNA, and then to
proteins, as well as the regulatory mechanisms of the products of the genes. DNA is the
material that holds heredity information. Stored in the nucleus of the cell, it is arranged
into regions called chromosomes, which carry the genes. Each gene consists of a long chain
of nucleotides which is designated to perform a specific function. Roughly speaking, a gene
transcribes into mRNA, which then translates into protein. Nonetheless, some parts of the
gene “splice out” – called introns, while the remaining parts –coding parts or exons– “splice
into” messenger RNA, out of which a portion is translated into protein. Transcription and
translation are one-way direction processes as depicted in Figure 1.1; they form what is known
as the central dogma of molecular biology. Based on the fact that different transcripts for
specific genes may lead to a different protein, we decided to analyze the gene expression and
quantification on both gene level as in Chapter 4, and more detailed on the transcription
level as in Chapters 2, 3, and 5.
The transcriptome or usually known as all RNAs is the repertoire of all DNA molecules
that transcribe into RNA and the events that are associated with the transcription pro-
cess. Unlike the genome, which is usually fixed except for DNA mutations, variations or
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Figure 1.1: Central dogma of molecular biology.
alterations, transcriptome analysis opens the door for studying a number of external fac-
tors involved in gene expression such as environmental conditions, regulatory proteins, gene
transport, and others. The transcriptome includes the gene transcript expression profiling
and alternative splicing activity. It comprehensively includes the overall messenger RNA
(mRNA) expression in one cell, which is also known as single-cell transcriptome. Alternative
splicing is a regulated process during gene expression that results in coding multiple variants
or isoforms of RNA, which are then tranlated into different proteins via open reading frames
(ORFs). In this process, particular exons of a gene may be included within or excluded from
the final transcript (processed mRNA produced from that gene) [1]. Figure 1.2 depicts two
different scenarios of transcriptions of the same gene to form two different proteins.
1.2 Cancer
Cancer is a very complex disease that can be defined as unusual growth of cells. The
defining feature of this disease is the rapid creation of abnormal cells that grow beyond
their usual boundaries. According to the World Health Organization (WHO), cancer is the
second leading cause of death world-wide [2]. Cancer starts by transforming healthy cells
into tumor cells in a multistage process that generally progresses from a pre-cancerous lesion
to a metastatic tumor. These changes are the result of the interaction between a person’s
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Figure 1.2: Alternative splicing allows a gene to transcribe into two or more different ways using different
combinations of exons to produce different proteins.
genetic factors and three categories of external agents, including but not limited to:
• physical carcinogens agents, such as ultraviolet and ionizing radiation.
• chemical carcinogens agents, such as asbestos, components of tobacco smoke, aflatoxin
(a food contaminant), and arsenic (a drinking water contaminant).
• biological carcinogens agents, such as infections from certain viruses, bacteria, or para-
sites [2].
Similarly, the staging cancer system was devised by Pierre Denoix to notate the differ-
ent stages of cancer while progression takes place [4]. This notation system is known as
Classification of Malignant Tumors (TNM), where:
• T describes the size of the primary tumor and whether it has invaded nearby tissue.
• N describes regional lymph nodes that are involved.
3
Figure 1.3: TNM stages of prostate cancer. Courtesy: Comprehensive Urology [5].
• M describes distant metastasis, namely, how cancer spreads from one organ of the body
to another distant organ.
In Chapter 3, we present an approach that is used to quantify transcript reads over TNM
classification to interpolate the progression for prostate cancer tumours. More details about
the stages and the sub-stages of the samples are included in that chapter. Figure 1.3 depicts
the normal and different TNM stages of prostate tissues.
Prostate is a gland in the male reproductive system, and prostate cancer is the develop-
ment of cancerous cells in the prostate. While the majority of prostate cancers metastasize
very slowly, some metastasize very fast [6]. The aggressiveness of prostate cancer can be
measured using Gleason score. Gleason score is a grading system which was introduced by
Dr. Donald Gleason to classify the cancer in the prostate tissue based upon its microscopic
4
Figure 1.4: Gleason score patterns which was drawn by Dr. Gleason Courtesy: [3].
appearance. The pathologist can determine the score based on collecting several details such
as tumor’s shape, tumor size, and which prostate tissue the tumor exists. The higher score
indicates greater risks and higher mortality. Cell morphology determines the structure, the
size, and how the shape of cells looks like such as cocci, bacilli, spiral shapes. The cancer
can be dominant or non dominant cell morphology in specific tissue based on whether or
not the majority of cells are cancer. The pathologist grade the dominant cell morphology
from 1 to 5 , and another score from 1 to 5 for the non dominant cell morphology. The total
addition of the two score form the total Gleason score that ranges from 2 to 10. Figure 1.4
depicts the Gleason scale patterns that pathologist can use to determine the score for both
dominant and non-dominant cell morphology.
Gleason score (pattern) descriptions are the following:
• Gleason pattern 1: is the most well-differentiated tumor pattern. It is a well-defined
nodule of single/separate, closely/densely packed, back-to-back gland pattern that does
not spread into adjacent healthy prostatic tissue. The glands are round or might be oval
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shaped and proportionally large, when comparing them to those of Gleason pattern 3
tumors.
• Gleason 2: is fairly well circumscribed nodule of single, separate glands. However, the
glands are looser in arrangement and not as uniform as in pattern 1. Minimal invasion
by neoplastic glands into the surrounding healthy prostate tissue may be seen. Similar
to Gleason 1, the glands are usually larger than those of Gleason 3 patterns, and are
round to oval in shape. Thus the main difference between Gleason 1 and 2 is the density
of packing of the glands seen and invasion is possible in Gleason 2, not in Gleason 1 by
definition.
• Gleason pattern 3: is a clearly infiltrative neoplasm, with extension into adjacent
healthy prostate tissue. The glands vary in size and shape and are often long/angular.
They are usually small to medium size/micro-glandular in comparison to Gleason 1-2
grades. The small glands of Gleason 3, in comparison to the small and poorly defined
glands of pattern 4, are distinct glandular units.
• Gleason pattern 4: glands are no longer single/separated glands similar to those seen
in patterns 1-3. They look fused together, difficult to distinguish, with rare lumen
formation compared to Gleason 1-3 which usually all have open lumens (spaces) within
the glands, or they can be cribriform-(denoting an anatomical structure that is pierced
by numerous small holes. Resembling the cribriform plate/similar to a sieve. An item
with many perforations). Fused glands are chains, nests, or groups of glands that are
no longer entirely separated by stroma. Fused glands contain occasional stroma giving
the appearance of partial separation of the glands.
• Gleason pattern 5: Neoplasms have no glandular differentiation (thus not resembling
normal prostate tissue at all). It contains sheets (groups of cells almost planar in
appearance (similar to the top of a box), solid cords, or individual cells [7].
Gleason scores are often grouped based on similar behavior: Grade 2-4 being well-
differentiated neoplasm, Grade 5-6 intermediate-grade neoplasm, Grade 7 moderately -
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poorly differentiated grade neoplasm, and Grade 8-10 high-grade neoplasm. We have de-
veloped a machine learning approaches to obtain markers for prostate cancer Gleason score
[8]and laterality (location in the tissue) [9].
On the other hand, breast cancer is the most common type of cancer in female population
worldwide [2]. Breast cancer can be classified using the TNM classification and molecular
subtypes. In Chapter 4, we present an approach used to analyze the gene expression of
breast cancer patients to find markers that are related to specific subtypes using supervised
machine learning methods.
The tumor tissue under the microscope suggest nonlinear structure which is known as
tumor heterogeneity. Heterogeneity may show distinct morphological and phenotypic pro-
files, including cellular morphology, gene expression, proliferation, metabolism, motility, and
metastatic potential. Tumor heterogeneity has been observed in many type of cancer, breast
and prostate cancers are not any exception [16]. Targeting heterogeneity for furthur anal-
ysis can be in experimental and computational side, single cell sequencing and bulk tumor
sequencing can be both applied in the coputational side; In the first, an indicual cell can
be entirely sequenced amd the mutational profiles for distict cells can be analyzed with no
ambguity. However, this method is lacking of sufficient number of cells to obtain statisti-
cal significance. While in the bulk tumor sequencing, identifying rare mutations is difficult
because of the low frequency in the (bulk) mixture of cells.
Perou and colleagues categorized the molecular subtypes of breast cancer based on the
relative expression of 500 differentially expressed genes [17, 18], the five intrinsic categories
including:
• Luminal A breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesterone-
receptor positive), HER2 negative.
• Luminal B breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesterone-
receptor positive), and either HER2 positive or HER2 negative with high levels of Ki-67.
• Triple-negative/basal-like breast cancer is hormone-receptor-negative (estrogen-receptor
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and progesterone-receptor negative) and HER2 negative.
• HER2-enriched breast cancer is hormone-receptor-negative (estrogen-receptor and progesterone-
receptor negative) and HER2 positive.
• Normal-like breast cancer is similar to luminal A, but is hormone-receptor positive
(estrogen-receptor and/or progesterone-receptor positive), and HER2 negative.
A recent research has introduced 10 molecular subtypes of Breast Cancer [10]. The aim of
this new subtype categorization is to obtain more separation in the largest subgroup of breast
cancer. In the 70% of breast cancers that are classified as estrogen-receptor positive/HER2-
negative in Luminal A, there is a tremendous heterogeneity; some groups of those patients
have different prognosis than others [13]. The genomic variation at a specific locus can lead
to a different expression for that gene. Curtis et al. generated a map of CNAs, CNVs,
and SNP for the new breast cancer classes. The integrative 10 classes which are named
InClust 1-10 have different clinical outcomes. Figure 1.5 shows the number of patients in
each InClust followed by the number of death from the specific disease between brackets
from the study [10].
1.3 Microarray
Chang et al introduced the microarray as anti-body microarray in 1983 [11]. In 1995, Schena
et al. used the microarray to monitor the expression of genes in parallel by reading comple-
mentary DNAs on glass using high-speed printing robotics [12]. After that, the microarray
industry established itself as the most used technology for reading gene expression with many
different industrial leaders in the market such as Affymetrix, Agilent, Applied Microarrays,
Arrayjet, Illumina, and others.
Microarray is capable to read the expressions of thousands of genes at the same time. a
microscope slides which known as DNA chips are positions to measure the gene expression
at the mRNA level that is known as transcriptome. Two mRNA samples, one from normal
tissue ( healthy) that is called reference sample and the other one from the cancer or some
8
Figure 1.5: The new breast cancer 10 subtypes clinical courtesy: [10], Kaplan–Meier plot of 15-years breast
cancer survival for each InClust.
other disease, are converted into complementary DNA (cDNA). if a gene from both samples
have a similar expression, the corresponding chip will appear as yellow, if the experiment
gene has expressed less than the reference gene, the correspondence chip will appear as red,
and if it is expresses more, the corresponding chip will appear as green.
9
1.4 Next-generation sequencing
Next generation sequencing (NGS) technology allows us to sequence the molecular events
fast at a very low cost, as well as higher sample throughput. The applications of NGS in
transcriptome analysis are commonly known as RNA Sequencing or RNA-Seq. There are
two main methods used to reconstruct the gene transcripts from sequenced reads. The first
one consists of comparing the reads to the reference genome for the same organism or a
similar known organism, while the second one consists of reconstructing the transcription
data from the reads without comparing it to known reference genome, which is known as de
novo assembly. Both techniques have been used in this thesis – see Chapter 2.
1.5 Machine learning
Machine learning is a branch of computer science that uses mathematical, statistical, and
logical techniques to make the machine learn from data without being programmed. In 1959,
Arthur Samuel came up with the name machine learning by combining artificial intelligence
in gaming and pattern recognition algorithms to make the machine learn from previous
experience. Data-driven predictions or decisions are the main purpose of machine learning.
Ever since, machine learning has evolved to include more applications and more challenges
to overcome by the machine including:
• Supervised learning, which means making the machine learn from labeled samples to
build the ability to predict or classify new unlabeled samples. Supervised learning
mainly includes classification and regression. We used these techniques in Chapters 2,
4, and 5.
• Unsupervised learning, in which the samples are not labeled, and hence, the machine
will attempt to group the samples based on similarities among them. Clustering is the
most popular application of unsupervised learning. In Chapter 3, we have contributed
to this area of learning by proposing a hierarchical clustering model that identifies
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outliers from time-series transcriptomic profiles. We further enhanced this algorithm
by extending the proposed method – see Chapter 4.
• Semi-supervised learning: since labeling samples is an expensive process, it starts with
labeling small number of samples, and then use the rest of the unlabeled samples in the
learning (training phase) which is more economically feasible. Mixing the unsupervised
techniques on the unlabeled data with the supervised techniques on both labeled and
unlabeled samples is a common technique in industry. The conjunction of labeled and
unlabeled samples may improve the accuracy of the learning system [14].
• Feature selection and extraction techniques are used to select or extract the most infor-
mative features (attributes) of the data that are relevant to the classification problem
that we are trying to solve. This includes feature selection (such as filter, wrapper, and
hybrid techniques), feature extraction, and dimensionality reduction techniques.
• Artificial neural network (ANN) and deep learning: In the attempt to mimic human
biological neural learning process, computer scientists created learning algorithms based
on connected nodes that can learn by forward propagation from the input layer to the
output layer going through the hidden layer. The nodes in the hidden layers have a
learning functions which is also known as activation functions. The nodes are connected
using weighted edges, which can be updated in the network back propagation phase to
reduce the error of the learning.
• Deep learning: A deeper neural networks or a neural network with multiple hidden layers
which recently emerge due to the revolutionary development in computer resources, such
as graphic processing units (GPU), and tensor processing unit (TPU). The complicated
deeper network are becoming more practical to optimize the machine learning; unlike
the ealier version of ANN, deep learning is about building multi-hidden layers of learning
rather than trying to understand the way that human brain works, which is known as
neuroscience technology [15].
• Time-series: Series of data that are generated from the same function or source in
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time order. Time series applications exist in our daily life, including financial stocks,
weather forecast, heart beat rate, speech, and others. In scientific domains, time series
applications almost exist in all fields such as signal processing, earthquake prediction
and astronomy.
1.6 RNA-Seq preprocessing
NGS technology generates a large number of reads (short sequences), which contain a vast
amount of genomic data. The sequencing process, however, comes with artifacts such as
biased sequences, sequence duplications, and ambiguous nucleotides. Preprocessing of the
sequences is mandatory for further downstream analysis. In Chapter 2, we present Zseq,
a linear time method that identifies the most informative genomic sequences and de-rank
the sequences with artifacts. The complexity of a word in any language is that have non-
repetitive terms, so the word cat has a high complexity and most likely to be a word, while
cacacaca has a low complexity and most likely not to be a word in English language. In
order to measure the complexity of RNA sequences, Zseq calculates the complexity of the
sequences by counting the number of unique k-mers in each sequence as its corresponding
score and also takes into the account other factors such as ambiguous nucleotides or high
GC-content percentage in k-mers. Based on a z-score threshold, Zseq sweeps through the
sequences again and filters those with a z-score less than the user-defined threshold.
The Zseq algorithm is able to provide a better mapping rate; it reduces the number of
ambiguous bases significantly in comparison with other methods. Evaluation of the filtered
reads has been conducted by aligning the reads and assembling the transcripts using the
reference genome as well as de novo assembly. The assembled transcripts show a better
discriminative ability to separate cancer and normal samples in comparison with another
state-of-the-art method in Chapter 2. Moreover, de novo assembled transcripts from the
reads filtered by Zseq have longer genomic sequences than other tested methods. Estimating
the threshold of the cutoff point is introduced using labeling rules with very optimistic
12
results.
1.7 Outlier detection from time-series cancer RNA-Seq data
Studying the abundance of selected mRNA species throughout prostate cancer progression
may provide insight into the molecular mechanisms that advance the disease. In Chapter 3,
we reveal that the combination of proper clustering, distance function and index validation
for clusters are suitable in identifying outlier transcripts, which exhibit different trends than
the majority of the transcripts. Unlike an earlier works in which we clustered the profiles
to find patterns as illustrated in Appendix A, this work focuses on finding the trend of
a transcript is the abundance throughout different stages of prostate cancer. In modeling
cancer progression, the stages are represented as time points, and the increase in transcript
abundance throughout those time points are cubic-spline interpolated. After profiling the
transcripts, we universally aligned the profile to a coordinate profile z [47], then we hierar-
chically clustered the profiles to find outliers profiles that have large distances and differently
trend than the other profiles.
Using a hierarchical clustering method for time-series profile data, we identified stage-
specific mRNA species termed outlier transcripts that exhibit unique trending patterns as
compared to most other transcripts during disease progression. This method is able to
identify those outliers rather than finding patterns among the trending transcripts compared
to the hierarchical clustering method that is based on the Euclidean distance. Our proposed
algorithm was able to identify the outliers and cluster them in singleton-clusters or in clusters
containing a small number of transcripts, while the hierarchical clustering based on Euclidean
distance was trying to find patterns rather than exclude the outliers.
A wet-lab experiment on a marker gene CAMK2G confirmed the results of the com-
putational model on a dataset of samples from a Chinese population. Genes related to
these outlier transcripts were found to be strongly associated with cancer, and in particular,
with prostate cancer. Further investigation of these outlier transcripts in prostate cancer
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may identify them as potential stage-specific indicators that can predict disease progression,
leading to novel drugs or therapies.
Studying gene expression through various time intervals of breast cancer survivability may
provide deeper insight into the recovery of the patients. Gene expression values are different
in various stages of progression of the disease. Discovery of gene biomarkers can be a crucial
step in predicting survivability and handling breast cancer patients. In Chapter 4, we present
an approach used to enhance a hierarchical clustering method to separate dissimilar groups
of genes in time-series data as outliers. These isolated outliers (genes that trend differently
from other genes) can serve as potential markers of breast cancer survivability. Noise is
undesirable case or unwanted case in data distribution, the noise can be generated randomly
or non-randomly. Outliers are cases who are removed from the main body of the data, where
the proximities of the outlier to the other cases are generaly small, in another words, the
measurment of the outlier is away from the mean of the other measurements in the same
class [21]. In supervised learning, the outlier can be determined by identifying the border of
the class using support vector machines [21] or anti-Bayesian [22]; this technique known as
one class classification.
Outliers can be studied to analyse unusual situation since the outlier can be a legitimate
case, while it is usually treated as noise or error in a measurment. It also may introduce
novelty in any distribution. Since cancer is unusual growth of the cells, unusual growth of
the cancerous cells over time needs to be carefully studied to analyze the nature of cancer,
in addition to the motives of the expression at some certain time points.
We partition the time axis (time points) into bins of length six months starting from 1-6
up to 55 months intervals and, for each gene, we average its expression level over all patients
who appear in a survival bin. Gene expressions throughout those time points are cubic
spline interpolated to create a trending profile for each gene. First, we universally align the
gene expression profiles to minimize the total area between them. Then, we cluster them
using a sliding window approach and hierarchical clustering based on minimum squared error
distances.
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To the best of our knowledge, this work is the first time-series model that is built on the
survival time of patients after the treatment. With this approach, we identified 60 genes
(including 36 oncogenes and 18 tumor suppressor genes) as potential biomarkers of breast
cancer survivability.
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Chapter 2
Zseq : an approach for preprocessing
next generation sequencing data
2.1 Introduction
A low-complexity sequence of nucleotides has highly biased distribution of nucleotides in a
way that makes the sequence less diverse of unique k-mers of nucleotides. The lower the
complexity of a sequence, the more likely that the sequence will be mapped to different parts
of the genome. In other words, when we process low-complex sequences, there is less chance
that we can align it to a specific part of the genome uniquely. This low level of certainty
regarding the real position of a sequence, makes it less desirable to be used.
Poly A/Poly T is a chain of A or T, used to prime the three and five sites in a genome
sequence during cDNA library preparation [6]. Poly A/T sequences may cause bias in the
reads. The intronic Poly A/T tails tend to splice out rather than staying between coding
exons [7]. The GC content represents the ratio of a G-C pair in the genome sequence. The
stop codons show a significantly high ratio of A-T nucleotides [8], while coding codons have
a higher GC content [9]. The GC content of a gene plays an important role in carrying
the genetic information. The GC content of the human genome varies among different
chromosomes. However, the average GC content of the human genome is 41% [10]. The
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representation of A+T sequences can be significantly lower, because in the preparation of a
standard library a gel slice is used and heated up to 50 ◦C, thereby increasing the bias of the
GC content [11].
Fastqc can be used to check the quality of the sequenced reads that is coming from high
throughput sequencing pipelines. It provides a modular set of analyses wether your data
should be preprocessed and which kind of biases or artifacts which the raw data may have
at each base pair position in the reads [12]. Fastqc can works FASTA and FASTQ format
where both are similar except that FASTQ provides a quality measurment of each sequenced
base pair. Fastqc is useful to view the content of the data before and after preprocessing the
sequences using tools such as Zseq.
There are different techniques that try to remove those sequences with low-complexity
patterns from samples. Morgulis et al. presented the symmetric DUST method [13], which
masks low-complexity regions in a sequence to overcome context sensitivity in calculating
the complexity score. Schmieder et al. proposed two methods to evaluate the sequence
complexity [14]. The first method is based on entropy as a measure. The second method,
which is a variant of the DUST algorithm based on BLAST search, filters out the low-
complexity score sequences. Both methods consider each triplet of nucleotides as a word.
One of the downsides of the previous methods is that they focus only on the complexity
of the sequences. This can be misleading in some cases due to the highly biased nature
of the sequences. In this chapter, we propose a novel method called Zseq, which decreases
the uniqueness score of highly biased regions, thereby filtering highly biased sequences and
low-complexity sequences.
2.1.1 Methods
Figure 2.1 depicts the process of finding reads with improved quality. Each module is ex-
plained in detail in the next few paragraphs.
In the first step, Zseq scans all the reads and calculates the uniqueness score for all reads.
The uniqueness score corresponding to each read is equal to the number of unique k-mers in
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Figure 2.1: Schematic representation of the process for filtering reads using the Zseq method.
that read. Zseq considers the default k-mer size, w, as 4-mers, which makes the vocabulary of
four nucleotides (A,T,C,G) to be 44 = 256 words. As the long reads may contain thousands
of nucleotides, the 3-mer size is not sufficient to measure the complexity of the reads. This
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Figure 2.2: Distribution of the normalized uniqueness scores for all reads in sample (SRR202054) (µ =
25.8169, σ = 7.1681).
is because a 3-mer word can exist many times in the same read without being considered as
unique, even when it is associated with different nucleotides each time. Zseq excludes the
5-mers of the low-complex/biased artifacts, such as ambiguous bases (N), PolyA/T and GC
content, from being unique by decreasing the unique score of the reads by one for each 2w
in order to reduce the chances of selecting this sequence later. The uniqueness score of each
read is then normalized by dividing it by the length of the read. The normalized uniqueness
scores of all reads are stored in a vector with the same order of the read in the input file.
Figure 2.2 shows the distribution of the normalized uniqueness scores for all reads for sample
SRR202054 from the prostate cancer data set used in the study of [16]. The x-axis shows
the normalized uniqueness scores, while the y-axis shows the number of reads. As shown in
the figure, the penalized sequences have a very small score down to -30. These are sequences
that have been generated using reads that contain long PolyA/T sequences, very high GC
content, or very high number of ambiguous nucleotides (N).
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In the next step, Zseq calculates the mean and standard deviation for the normalized
uniqueness scores. The mean of the normalized uniqueness scores of all reads is calculated
in the first loop. The variance is also calculated linearly using a Na¨ıve algorithm to reduce
the cost of this step. The standard deviation is calculated from the variance of the vector of
the normalized uniqueness scores.
Next, for each normalized uniqueness score, we calculate the z-score using the mean, µ,
and the standard deviation, σ, as follows:
z = (s− µ)/σ. (2.1)
The z-score represents how many standard deviations the normalized uniqueness score of
the read is away from the mean µ for all normalized uniqueness scores. In other words, if
a read has a z-score of 0, it means that the read has the normalized uniqueness score of µ,
while a z-score of value 1 means that the normalized uniqueness score is away exactly one
standard deviation from the µ. Figure 2.3 shows the z-scores for all reads in the sample
(SRR202054), where the x-axis is the z-score of the normalized uniqueness scores, while the
y-axis indicates how many reads a particular z-score has in the sample.
Finally, the user-adjustable threshold θ is used to determine whether or not to select the
reads, if the z-score of the normalized uniqueness score of the reads is greater than or equal
to θ, the read will be selected; otherwise, it will be filtered out.
2.1.2 Estimating the cuttoff point
A data driven method based on the labeling rules is used to filter out the reads with low
uniqueness score. The method automatically finds the cutoff point c to compensate θ in the
histogram of reads’ uniqueness scores and removes those reads whose uniqueness score is less
than c. The labeling rules model calculates the first quartile q1 and third quartile q3 using
the mean and the standard deviation which both are in the first loop through the reads. The
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Figure 2.3: Distribution of the z-scores of the normalized uniqueness scores corresponding to each read for
sample (SRR202054).
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cut-off point is calculated as follows:
c = q1− g(q3− q1) (2.2)
where g is the g-factor that can be calculated as follows:
g = (h− q1)/h (2.3)
with h being the highest value in the histogram of reads’ uniqueness scores. After calculating
the cut-off point c, the method sweeps again throughout the reads and selects those that
have uniqueness score ≤ c
2.2 Results
In our experiments, we used the prostate cancer data set utilized in the study of [16]. The
data set is publicly available in NCBI Gene Expression Omnibus (GEO) under accession no.
GSE29155. It contains 11 samples in total, where seven of them belong to tumor tissues
and the remaining four samples are benign. We measured the GC content and the number
of ambiguous bases of the outcomes of each method, and then aligned the results of both
methods to the human genome using Tophat2 as the alignment method [18].
DUST takes a value that ranges from 0 and 100 as the complexity threshold, while Zseq
takes a z-score value as a complexity threshold, which shows how many standard deviations
the normalized uniqueness score of the read is away from the mean. For the DUST method
we chose the value 5 as the threshold, which means that the value of the complexity of the
read has to be greater than or equal to 5 to be selected; otherwise, DUST will ignore the
read. For Zseq, we have chosen -1.5 as the value of the threshold, which makes the read
good to be selected if the z-score of that read is greater than or equal to -1.5. The reason
behind selecting these two thresholds is that both methods filter almost the same number of
reads in each sample.
The filtered reads using Zseq have less GC content than the filtered reads using DUST. It
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Figure 2.4: Percentage of GC content for all filtered reads using the Zseq histogram (a) with µ = 52.63%
and σ = 12.08%.
Figure 2.5: Percentage of GC content for all filtered reads using the DUST histogram with µ = 53.09% and
σ = 12.36%.
also has smaller standard deviation which makes the reads centered more around the mean
than DUST. Figure 2.4 and Figure 2.5show the GC content distributions for both methods
applied on the same sample set (SRR202058).
Zseq shows a slight improvement in reducing the GC content, mapping rate and mapping
time, while dropping the number of ambiguous bases drastically in comparison with DUST.
Table 2.1 shows that the number of ambiguous bases, N, in the filtered reads using Zseq have
drastically decreased compared with the ambiguous bases that have been filtered out using
DUST in all samples. For example, the number of occurrences of N in sample SRR202054
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for filtered reads by DUST is 19,177, while there are only 11,135 filtered reads using Zseq for
the same sample. The results indicate that Zseq slightly shrunk the GC content percentage
distribution and reduced the mean of the GC content percentage. For sample SRR202055,
the mean of the GC content is 52.48± 12.10% using Zseq, which is less than 52.91± 12.38%
obtained using DUST. Zseq also shows better mapping alignment for the filtered reads than
DUST for most of the samples. For example, in sample SRR202061, the reads filtered by
Zseq have 79.20% mapping rate, which is greater than 77.90% mapping rate for reads filtered
by DUST, the only exception is sample SRR202062, which shows a similar mapping rate of
71.30% for both DUST and Zseq.
Table 2.1: Comparison of the results of applying Zseq on samples from the prostate cancer data set as a
result of applying DUST on the same samples.
Original Zseq DUST
Sample Number Occurrences of N Mean GC content Mapping rate Occurrences of N Mean GC content Mapping rate Occurrences of N Mean GC content Mapping rate
SRR202054 40,690 52.82± 14.06% 91.50% 11,135 52.61± 12.20% 93.00% 19,177 52.89± 12.33% 92.80%
SRR202055 42,965 53.01± 13.74% 91.20% 9,336 52.48± 12.10% 92.40% 19,470 52.91± 12.38% 92.10%
SRR202056 40,243 52.94± 13.99% 91.40% 10,721 52.67± 12.22% 92.80% 18,336 52.95± 12.36% 92.60%
SRR202057 42,630 52.94± 13.94% 91.30% 10,403 52.65± 12.22% 92.60% 20,018 52.93± 12.36% 92.40%
SRR202058 16,643 53.12± 14.03% 91.00% 14,023 52.63± 12.08% 92.40% 16,198 53.09± 12.36% 92.30%
SRR202059 17,741 52.56± 13.88% 90.70% 14,042 52.18± 12.02% 92.00% 17,091 52.61± 12.28% 91.90%
SRR202060 19,958 53.44± 13.98% 90.90% 13,775 53.23± 12.09% 92.40% 17,281 53.51± 12.21% 92.30%
SRR202061 2,156 50.06± 11.50% 77.00% 1,849 48.87± 9.96% 79.20% 2,100 49.95± 11.12% 77.90%
SRR202062 5,837 52.81± 13.64% 69.10% 5,122 52.69± 11.77% 71.30% 5,466 52.91± 11.84% 71.30%
2.2.1 De novo sequences validation
Using Trinity de novo assembler [19], transcripts have been reconstructed for the original
reads of sample SRR202058, reads that have been filtered by DUST and reads that have been
filtered by Zseq. In the next step, all three sets of constructed transcripts were evaluated by
searching the assembled transcripts with the human genome sequences using BLAST [20].
The set of the reconstructed transcript using the filtered reads by Zseq contains a higher
number of long sequences in comparison with the other two sets. Figure 2.6, 2.7, and 2.8
show the meaningful sequences for each set. Some of the sequences, which were built using
the reads filtered by Zseq, have a length of 1000 bp or more along with high alignment score;
while the sequence length is slightly more than 300 bp using the reads filtered by DUST and
200 bp for the original reads without filtering.
27
Figure 2.6: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using original reads.
Figure 2.7: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using reads filtered by DUST.
2.2.2 Machine learning validation
In another experiment, we used an independent data set that contains 12 samples (six tumor
and six matched normal) [10]. Using these samples, three data sets were generated, one from
the original reads, one by applying DUST on the reads, and the third one by applying Zseq
on the reads for all samples. In the next step, all reads corresponding to each data set have
been aligned to human genome hg19 using Tophat2 [18] and Cuﬄinks assembler [22] with
default parameters to assemble the transcripts to the human genome and estimate their
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Figure 2.8: Biologically meaningful human genomic sequences found using BLAST. De novo assembled
transcripts using reads filtered by Zseq.
abundance, which is measured by FPKM value (fragments per kilo bases of exons for per
million mapped reads). Table 2.2 shows the the average mapping rate of reads filtered by
each method. Each generated data set using filtered reads has 43,497 features (transcripts)
Table 2.2: Average mapping rate of transcripts using the data set generated by the original reads, reads
filtered by DUST and reads filtered by Zseq.
Original DUST Z-seq
88.90% 90.10% 90.40%
with FPKM values. Also, each of the 12 samples was labeled by cancer or matched benign.
The FPKM value equals 0 if the transcript has not been found to be present in that sample.
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We measured the number of transcripts that can individually separate all cancer samples
from normal samples perfectly, with 100% accuracy. In other words, we want to compute
the number of transcripts generated using filtered reads by each method, in such a way that
the FPKM values corresponding to cancer samples can be separated from of those FPKM
of normal samples. Figure 2.9 depicts two transcripts; transcript a has clearly separable
FPKM values, while in transcript b, the FPKM values cannot be separated accurately.
Figure 2.9: An example of two transcripts, one with separable FPKM values (a), and another transcript
with inseparable FPKM values (b).
Table 2.3 shows the number of transcripts that contain separable FPKM values. These
results indicate that applying Zseq influences the alignment tool and assembler to quantify
more meaningful transcripts that can discriminate cancer and normal samples in comparison
with the DUST method and original reads.
Table 2.3: the number of discriminative transcripts for each of the three data sets.
Data set n of discriminative transcripts
Original 167
Filtered by Dust 159
Filtered by Zseq 231
Moreover, using Chi2 statistical test [6] on the 231 discriminative transcripts from the Zseq
data set, the NM 001145410 transcript corresponding to NONO gene was the most significant
transcript among all other transcripts in all three data sets. NONO is known to regulate in
different types of cancer such as breast and prostate cancer [24, 25]. Next, a support vector
machine (SVM) with linear kernel (SVM-L) was applied on the three data sets using this
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Table 2.4: Some artifacts measurements of prostate cancer samples which were preprocessed by EC-Zseq.
EC-Zseq
Sample
Number
Occurrences
of N
Mean GC
content
Mapping
Rate
SRR202054 33,124
52.71 ±
13.40%
93.40%
SRR202055 27,890
52.91 ±
12.76%
93.30%
SRR202056 34,453
52.82 ±
13.07%
93.50%
SRR202057 30,321
52.68 ±
12.52%
93.40%
SRR202058 14,760
52.87 ±
13.43%
92.90%
SRR202059 15,203
52.18 ±
12.62%
92.80%
SRR202060 16,704
53.31 ±
12.09%
92.70%
SRR202061 1,926
49.11 ±
10.62%
79.70%
SRR202062 5,484
532.70 ±
12.47%
72.10%
transcript as feature. SVM is a supervised learning machine that tries to find an optimal
separating hyperplane between classes [26]. Using a leave-two-out cross-validation scheme,
the classification returns 100% accuracy for the Zseq data set, 91.66% for the DUST data
set, while it was down to 83.33% in the original reads data set.
2.2.3 Result for estimated cutoff point Zseq
The results of the estimated cutoff point Zseq as shown in Table 2.4 and Table 2.5 suggested
that the method does not find the optimal point. The result of Zseq on the prostate cancer
data set using the threshold θ = -1.5 in prevouis section out performed the result of the
EC-Zseq. Despite having better mapping rate, EC-Zseq falls short in mean GC content to
Zseq with θ, in number of ambiguous nucleotides compared to DUST and Zseq with θ, and
in number of decisive transcript compared to Zseq with θ. However, EC-Zseq still shows
better results than the original data set or pre-processing the data set using DUST method.
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Table 2.5: the number of decisive transcripts for the data set that was pre-processed by EC-Zseq.
Data set n of Decisive transcripts
pre-processed by EC-Zseq 222
2.3 Conclusion
We have presented a novel method for filtering the reads that reduces the number of biased,
duplicate or ambiguous sequences. Our method finds the complexity of the sequences by
assigning a unique score to each read. Using a user-defined threshold, the user can filter
the reads with a score less than the threshold. Applying the proposed method on real
samples shows that the Zseq algorithm is statistically sound and provides a better mapping
rate, while it significantly reduces the number of ambiguous bases in comparison with other
state-of-the-art methods. Estimating the cutoff point using labeling rules shows a good
result. The Zseq method is publicly available and can be accessed using the following link:
http://sourceforge.net/projects/zseq/.
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Chapter 3
Identifying biomarkers of prostate
cancer progression using transcript
outliers from time-series clusters
3.1 Background
Clustering time-series methods have been used in bioinformatics mainly for gene expression
profiles [1, 2]. Rueda et al. proposed a clustering method that, first, aligns the gene ex-
pression profiles together to minimize the total areas between the gene profiles, and then
clusters the profiles using an agglomerative clustering method based on the furthest neighbor
distance between each pair of clusters [3]. Also, they used a modified version of the I-index
cluster validity function [4] to validate the optimum number of clusters. Subhani et al. pro-
posed a cubic spline interpolation for gene expression profiles, then clustering gene profiles
using k-means clustering with multiple alignment input (k-MCMA) and expectation maxi-
mization clustering with multiple alignment (EMMA), and compared it with the variation
co-expression detection (VCD) method [5]. Different cluster validity indices have been used
in this work including Davies-Bouldin’s (DB) index [6]. Each time-series clustering method
uses a distance function to define the similarity between samples as well as between clusters.
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Different biological clustering models need different distance functions and the difference
between the best distance function and the others can be substantial [7]. Distance functions
can be divided into metric and non-metric methods.
Euclidean distance is one of the most common used distance to find the dissimilarity
between gene expression profiles [8,9]. Vedell et al. [8] used the hybrid dynamic dendrogram
cutting method, from the R/dynamicTree Cut package, to obtain transcript abundance pro-
files. The samples from rats liver were hierarchically clustered based on Euclidean distance.
Gene expression changes were identified by reverse transcriptase polymerase chain reaction
in rat livers which was treated with Targret in for three-time points 2, 7, and 21 days. These
showed similar gene expression changes at all three-time points, arguing some steady-state
effect. Different patterns of gene expression allowed one to predict certain physiologic con-
sequences of agonist treatment. Ferrari et al. [9] proposed a clustering method by using
meta-learning systems. They introduce a new problem characterization mechanism and two
ranking combination schemes. From the clustering problems, the method extracts three sets
of meta-attributes; the first uses the problems’ attributes as traditional direct characteriza-
tion method, the second method applies an indirect method based on the Euclidean distance
between objects, and the third one combines the first two methods. Euclidean distance and
other correlation measurements require normalization.
Chiu et al. [2] interpolated gene expression using cubic B-splines interpolation to estimate
the missing values in the time-series, utilizing sliding-window, affinity propagation, gene
relativity graph and a consensus process to cluster the time-series gene expression models.
Chira et al. [10] proposed a shape-output clustering method that analyzes time series data
to study co-expressed gene growth patterns. The changes in the RNA abundance levels have
been used to cluster genes based on their shape measured over time in several samples. It has
been shown that there is a relationship between production variables and gene expressions .
Natural cubic spline interpolation is a spline interpolation method to approximate a func-
tion from discrete points. Cubic spline interpolation can correlate the data points efficiently
and effectively [11]. Previous works have primarily focused on clustering similar gene expres-
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sion profiles. Usually, the developmental growth of a process through time is polynomial. To
the best of our knowledge, our study is the first to assume that cancer stages are time points
to approximate disease progression. The assumption stems from the fact that any biological
function is a continuous process and prostate cancer progression is not any exception. Most
of studies apply clustering to detect outliers. Pamula et al. proposed k-means clustering to
capture outliers [12], while Marghny et al. used a genetic k-means model that focuses on
detecting outliers and removing them since they serves as noise [13].
In this work, outlier transcripts are selected because they trend in a different way than
other transcripts and hence may serve as a biological indicator of change. We provide some
biological insight into the transcripts isolated and discuss the potential use of this information
for biological insight into cancer progression. This may provide biological insight into the
relationship between the abnormal expression of outlier transcripts and cancer progression.
3.2 Materials and methods
RNA-seq data generated from prostate cancer patient tumor samples spanning the spec-
trum of stage/sub-stages of disease progression was preprocessed and changes in transcript
abundance over time assessed using cubic spline interpolation. After universally aligning
transcript profiles, they were clustered using an agglomerative clustering approach based
on the area between the profiles as distance measure. For the wet lab experiment, the
cell culture is MNU series of prostate cancer cell lines (WPE1-NA22, WPE1-NB14, WPE1-
NB11, WPE1-NB26), which mimic stages in prostatic intra-epithelial neoplasia (PIN) and
progression to invasive cancer. Cells were cultured using complete keratinocyte serum free
(KSF) medium supplemented with epidermal growth factor and bovine pituitary extract
(Invitrogen). QRT-PCR. Total RNA was extracted using the Qiagen RNeasy Kit as per
manufactures instructions. RNA was subjected to cDNA synthesis using Quanta qScript
cDNA SuperMix. Quantitative PCRs were performed using the Fast SYBR-Green mas-
ter mix (Thermo Fisher). To calculate relative gene expression, GAPDH mRNA was am-
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Table 3.1: Tumor samples that are analyzed from the first dataset.
Stage/Sub-stage Samples
T1cN0M0 ERR031038
T2aN0M0 ERR031032
T2bN0M0 ERR031026
T2cN0M0
ERR299297
ERR031044
ERR299295
T3bN0M0 ERR031040
T4N0M0 ERR299298
plified as an internal control. The following primer sequences were designed for GAPDH
(5’-GCACCGTCAAGGCTGAGAAC-3’ and 5’-GGATCTCGCTCCTGGAAGATG-3’) and
CAMK2G (5’-GGGACCTGAAGCCTGAGAAC-3’ and 5’-GGAGCCCTTGATCCCATCTG-
3’).
3.2.1 Data pre-processing
The first dataset contains samples from the Chinese population. Using eight of 28 paired
samples (matched tumor and adjacent normal) in a data set from NCBI-SRA:ERP000550,
we preprocessed each sample using Zseq [14] and then aligning its mRNA reads to the human
reference genome hg19. We then constructed a database of all expressed transcripts. Fig-
ure 3.1 depicts the preprocessing pipeline starting with aligning the reads corresponding to
each sample using Tophat2, which is a splicing junction mapper that utilizes the short read
alignment Bowtie. The accepted hits of the aligned reads are used to construct the gene
transcripts for Homo sapiens using Cuﬄinks [16] which assembles the transcripts guided
by the transcript annotation and estimates the abundance of each transcript. The second
dataset from NCBI-SRA:GSE54460 contains 106 samples from the North American popula-
tion [17]. We processed the samples using Zseq [14], then aligned the reads and constructed
the transcripts using STAR [17] and RSEM [19].
Table 3.1 shows the list of samples used in this work. The stage of each sample is indicated
in the number following T, and sub-stage as a lower case letter following the number (ex.
T1c refers to stage 1 and sub-stage c). All the samples used in this study have no lymph
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 RNA-Seq Samples 
Aligning Reads 
Accepted Hits 
Reconstructing Transcripts 
Assembeled 
Transcripts 
Figure 3.1: Preprocessing pipeline for each sample in the data set.
node involvement and are non-metastatic (indicated by N0M0). Each sample in Table 3.1
had to go through the pre-processing pipeline to assemble the transcripts of that sample’s
mRNA reads.
By tracking changes in the relative abundance of transcripts with a common transcription
start site, we identified changes in splicing for each stage/sub-stage. We found differentially
expressed transcripts in correlation with various prostate cancer stages/sub-stages by esti-
mating abundance of transcripts corresponding to each of these stages. For this, we used
Cuffdiff, which is a utility included in the Cuﬄinks package that uses accepted hits from the
aligned reads from each stage/sub-stage alongside the merge of all assembled transcripts,
and then uses statistical approaches to determine the differentially expressed genes and
transcripts in each of the cancer stages/sub-stages.
In the next step, a time-series data set was created from differentially expressed transcripts
throughout prostate cancer stages/sub-stages. The features of this data set are stage/sub-
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stages which are explained in Table 3.2. The abundance of the transcript at each stage/sub-
stage measured by Fragments Per Kilobase of transcript per Million mapped reads FPKM,
while the samples are the transcripts that have at least one significant FPKM value at one
of the stages/sub-stages. Totally, 19,698 transcript profiles have been extracted, where each
profile represents a sample in the proposed time-series model. The log of each FPKM values
of the profiles at all stages was calculated to reflect the fold change of the transcript expression
throughout different stages/sub-stages. The final data set contains the log(FPKM) value for
each feature for all profiles.
Table 3.2: Staging and description of the prostate cancer patent cohort [18].
Prostate
stage
Description
T1c The tumour is not detectable via
imaging techniques. Cancer is de-
tected using a needle biopsy per-
formed due to an elevated serum
PSA.
T2a The tumour is in half, or less than
half, of one of the prostate glands
two lobes.
T2b The tumour is in more than half of
one lobe, but is not in both lobes.
T2c The tumour is in both lobes but con-
fined within the prostatic capsule.
T3b The tumour has invaded one or both
of the seminal vesicles.
T4 The tumour rises to other organs
3.2.2 Natural cubic spline interpolation
Subhani et al. [5] reformulated the natural cubic spline interpolations of the time-series
profiles using arbitrary functions that are continuously integrable on a finite interval [5]. In
this work, we have utilized the reformulated cubic spline method to interpolate all profiles to
represent the transcript profile through prostate cancer progression. For profile x(t), where
t is a vector that represent time points [t1, t2, ..., tn], x(t) is interpolated continuously as:
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x(t) =

x1(t) if t1 < t < t2,
xj(t) if tj−1 < tj < tj+1,
xn−1(t) if tn−1 < t < tn.
(3.1)
where
xj(t) = xj3(t− tj)3 + xj2(t− tj)2 + xj1(t− tj)1 + xj0.(t− tj) (3.2)
xj(t) interpolates x(t) in interval [tj, tj+1], with spline coefficients xjk ∈ R, for 1 ≤ j ≤
n− 1 and 0 ≤ k ≤ 3, the interpolated x(t) spline has the natural condition,which means the
first and second derivatives of the spline at each interval xj(t) equals to zero.
Figure 3.2-a) shows the interpolated profiles for all 19,698 extracted transcripts profiles.
3.2.3 Universal alignment
Given data set X={x1(t), x2(t), ..xm(t} where m is the number of profiles. Cubic spline
interpolated profiles were universally aligned by shifting the interpolated transcript profiles
in such away that the integrated squared error between any two of those profiles is minimal.
Subhani et al. enhanced the pairwise alignment for all possible pair of profiles by aligning
all profiles into one particular profile z(t) = 0 (universal alignment), then proving both
approaches will achieve the same results. Figure3.2-b) shows the universal alignment for all
profiles.
3.2.4 Distance function
Based on the pairwise alignment between two profiles x(t) and y(t) , the distance between
them after aligning, vertical shifting, y(t) to x(t) is the area a between the two curves in
such way that a is the minimum square error; in other words, shifting y(t) to obtain the
minimum possible area between the two curves.
amin =
∫ tn
0
[x(t)− y(t)]dt (3.3)
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Figure 3.2: The 19,698 interpolated transcript profiles, each profile consists of the log(FPKM) values of the
transcripts expressions throughout prostate cancer stages/sub-stages(a), the profiles after universal align-
ment(b).
All profiles are aligned to the profile z(t)in such a way that distance between each profile
and z(t) is minimized; then, the distance matrix D between all profiles is calculated based
on the result of equation 3.3 between each possible pair from all profiles.
Profile clustering
The idea of detecting outliers using one of the clustering methods is to single out the profile
that is less similar to the other profiles. Then we place it in either a cluster of one pro-
file, or a cluster with a very small number of profiles with similar trend. To achieve this
goal, an agglomerative clustering method has been implemented to hierarchically cluster the
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profiles based on the maximum dissimilarity with the other profiles in a new cluster. The
agglomerative clustering method start from the number of profiles as the number of clusters,
in which each cluster contains one profile, and then continues merging the nearest clusters.
The distance between two clusters C1 and C2 determined by the distance between the fur-
thest profiles v and w where profile v ∈ C1 while w ∈ C2; the constructed D matrix is used
to determine the distance between v and w. The merging process between clusters continues
repeatedly until it reaches the desired number of clusters k.
3.2.5 Determining the desired number of clusters
The desired number of cluster k is determined using Profile Alignment and Agglomerative
Clustering (PAAC) index. PAAC index is an upgraded version of I-index by Rueda et al.
to solve the problem of penalizing the index value for the large number of clusters in the
I-index [3]. Visualizing the clusters’ profiles for each different number of cluster k, and the
visual representations of PAAC values for different k helps to select the best k.
PAAC was applied on both the proposed method and the hierarchical clustering method
based on Euclidean distance. For the proposed method, the PAAC values chart as shown in
Figure 3.3 shows that the PAAC value peaks when k = 31 and then start declining with no
sign of improvement for k > 31. While the PAAC values for the latter method suggests that
PAAC value peaks when k = 8 and start steadily declining for k > 8 as shown in Figure 3.4,
we kept measuring it up to k = 31 to check whether or not the value of PAAC may match
for both methods when k = 31.
3.3 Results and discussions
The method was implemented using Matlab, applied on the outcome data set from the
preprocessing pipeline. The agglomerative clustering showed a discriminative ability towards
outliers. The desired number of clusters was carefully chosen using validity indices as well
as visual observation of the clusters. Using validity indices for a different number of clusters,
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Figure 3.3: PAAC values for the proposed method for the first data set.
0.00E+00
1.00E+03
2.00E+03
3.00E+03
4.00E+03
5.00E+03
6.00E+03
7.00E+03
8.00E+03
9.00E+03
1.00E+04
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
PA
AC
 in
de
x 
va
lu
e 
k number of clusters
Figure 3.4: PAAC values for the hierarchical clustering based on Euclidean distance for the first data set.
PAAC suggested 31 as the optimum number of clusters for p = 2 and q=0.7, where q
is the coefficient of normalizing the number of clusters increment and p the coefficient of
the degree of the index. Cluster 2, which includes the majority of the transcripts (19,656
profiles, to be exact), is the background cluster as shown in Figure 3.7, where the rest of the
clusters are those that contain the outliers profiles as shown in Figures 3.9 and 3.10. The
hierarchical clustering based on the Euclidean distance clustered the profiles into 8 clusters
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Figure 3.5: PAAC values for the proposed method for the second data set.
0.18
0.19
0.2
0.21
0.22
0.23
0.24
0.25
11 16 21 26 31 36 41 46 51
P
A
A
C
 in
d
ex
 v
al
u
e
k number of clusters
Figure 3.6: PAAC values for the hierarchical clustering based on Euclidean distance for the second data set.
based on the suggestion of PAAC analysis, which was addressed earlier. Despite having less
number of clusters than the proposed method, the main cluster of the hierarchical method
has less number of profiles (18,784) compared to the proposed method, and the main cluster
of hierarchical missing many of the transcripts on the main trend as shown in Figure 3.8,
while the proposed method’s main cluster has a trimmed-looking profiles, where the outlier
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Figure 3.7: The first dataset: cluster 2 - main cluster for the proposed method.
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Figure 3.8: The first dataset: cluster 2 - main cluster for the hierarchical clustering based on Euclidean
distance method.
transcripts are removed.
3.3.1 Biological prioritization of transcripts
There is no overlapped transcripts between the pulled out list from the two dataset. The
two datasets are taking from different populations, where the first one was sampled from
Chinese populations while the second one was sampled from North American populations.
There are many differences from the genomic side between the two populations. For both
datasets, some of the genes corresponding to outlier transcripts are shown to be involved in
prostate cancer. Tables 3.3, 3.4 show these genes, their corresponding detected transcripts,
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Figure 3.9: The first dataset: clusters 1 to 16 of 31 distinct clusters detected by our proposed model.
and the cluster number shown in Figures 3.9 and 3.10. Some other genes are involved in
other types of cancers were also detected as outliers.
The STMN1 gene codes for Stathmin 1, an intracellular phosphoprotein that is upregu-
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Figure 3.10: The first dataset: clusters 17 to 31 of 31 distinct clusters detected by our proposed model.
lated in most epithelial cancers, including prostate cancer. Increased expression levels are
correlated with poor prognosis and disease progression. STMN1 phosphorylation is required
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Figure 3.11: The second dataset: clusters 1 to 12 of 20 distinct clusters detected by our proposed model.
for microtubule assembly during mitosis and constitutive phosphorylation may cause oncoge-
nesis. Decreased levels of STMN1 leads to epithelial-mesenchymal transition and metastasis
through p38 and TGF-B mechanisms. As a result, it has been suggested that the expression
levels of STMN1 may be stage dependent [20].
The gene product of calcium/calmodulin dependent protein kinase II gamma (CAMK2G)
is one of four subunits belonging to the multifunctional serine/threonine protein kinase fam-
ily. CAMK2G has been shown to be an enhancer of cell growth and survival in many
cancers including leukemia, lung cancer and liver cancer [21–23] (1-3). CAMK2G is also
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Figure 3.12: The second dataset: clusters 12 to 20 of 20 distinct clusters detected by our proposed model.
known to interact with many tumourigenic signalling pathways such as β-catenin, NF-κB
and Stat3 [21,23]
Runt-Related Transcription Factor 3 (RUNX3) gene product is frequently downregulated
in prostate cancer [24]. Decreased levels of RUNX3 lead to increased vascular endothelial
growth factor (VEGF) secretion and thereby increased angiogenesis. RUNX3 downregulation
also plays a role in both tumorigenesis and metastasis through dysregulation of TIMP-
Table 3.3: Genes and transcripts that correspond to prostate cancer were clustered as outliers for the first
dataset.
Gene Transcripts
Cluster
number
STMN1 NM 005563 29
CAMK2G NM 001222 19
RUNX3 NM 004350 22
MSMB NM 002443 31
PLA2G2A NM 001161728 8
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Table 3.4: Genes and transcripts that correspond to prostate cancer were clustered as outliers for the second
dataset.
Gene Transcripts
Cluster
number
FAM27L NR 028336 1
DMKN NR 033746 5
ACSM3 NM 005622 8
NUDT19 NM 001105570 11
ACP1 NR 024080 12
POLR2A NM 000937 18
2/MMP-2 levels [24].
The microseminoprotein beta (MSMB) gene encodes prostate secretory protein 94, a
member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells
of the prostate gland and secreted into the seminal plasma. It has been shown that the
expression of this gene is decreased in prostate cancer [25, 26]. Its mechanism as a tumor
suppressor is unclear, but may involve suppressing cell growth and fungicidal activity [27].
The PLA2G2A gene codes for the Phospholipase A2 group 2A extracellular enzyme that
plays a role in both tumorigenesis and the inflammatory response [28]. PLA2G2A has
been shown to be upregulated in prostate cancer and is associated with, a poor response to
chemotherapy as well as an overall poor prognosis. It has been suggested that the PLA2G2A
enzyme might suppress genes that are induced by interferons [29], and is a downstream target
of the HER/HER2 pathway [28].
DMKN gene in the second dataset cluster 6 was associated with prostate cancer in earlier
studies [30,31]. Srivastava et al. sequenced whole genome of 28 samples, and they identified
65 gene mutations present with higher confidence in at least one of the 14 prostate tumors
analyzed, DMKN was one of them. Out of 186 genes were found to be downregulated by
miR-138-5p. Gao et al. identified 5 potential targets including DMKN, EIF4EBP1, NINJ1,
PER1 and ST6GALNAC4 in prostate cancer cell [31]. Many of the genes related to the
transcripts identified from the second dataset were already proven to be linked to certain
cancers. Rotunno et al. finding suggests the use of APC1 gene expression’s from peripheral
whole blood (PWB) can be used as a marker of stage I Lung Adenocarcinoma [32]. Ruan et
53
al. findings indicate that ACSM3 is a novel prognostic marker and a potential therapeutic
target for hepatocellular carcinoma(HCC) [33]. Sayagues et al. suggest that disruption of
the FAM27L gene may play a role in the malignant transformation and/or the metastasis
of collateral tumors into the liver [34]. Wang et al. detailed that the nudix hydroxylase
(NUDT) family of genes may have notable roles in cancer growth and metastasis. Their
study determined the prognostic ability of NUDT genes in clear cell renal cell carcinoma
(ccRCC) [35]. Yoo et al. findings suggest that POLR2A can influence prognosis in early-
stage of non-small cell lung cancer (NSCLC) patients [36].
Biological validation of CAMKG2
Using the MNU cell line series that mimic early through late stages of progression we isolated
mRNA and studied the relative transcript abundance of CAMK2G using qRT-PCR. We
determined that the biological data achieved a trend that mimicked what was predicted in
our computational model as Figure 3.13. In the second dataset NM172171 transcript for
CAMK2G is trending as seen in Figure 3.14. Overall trending of this CAMK2G transcript
which is extracted from the North American dataset is different from the CAMK2G outlier
transcript which is extracted from the Chinese dataset. However, the trending is dropping
down in the latest stage is similar is similar for both of them, and also similar to the one
pulled from the wet-lab experiment.
Conclusions
This work introduces a time-series model of interpolating transcripts expression values
throughout cancer stages. A prostate cancer data set from Chinese population were prepro-
cessed to form time-series profiles that contain the expression values at each stage. Those
profiles were clustered by an agglomerative clustering method based on area between the
profiles as a distance. The method was able to discriminate the outliers who trend differ-
ent than the other profiles. Related genes with those outliers transcripts were found to be
strongly related to cancer in general, and prostate cancer in particular.
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Figure 3.13: Comparison of CAMK2G mRNA expression in prostate cancer cells mimicking prostate cancer
progression. QRT-PCR was performed to determine relative mRNA expression of CAMK2G in the MNU
series of prostate cancer cell lines that mimic early through to late stages of progression (NA22, stage 1 ;
NB14, stage 2; NB11, stage 3; and NB26, stage 4). ∗p < 0.05, n = 3.
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Figure 3.14: CAMK2G - NM172171 transcript in the second dataset.
A wet lab experiment was conducted on camk2g gene which was identified as an outlier
in the first dataset, it mimicked what was predicted in our computational model. Further
wet lab experiments on identified markers is the next step to explore the biological functions
of these markers throughout different prostate cancer stages. Some of these markers may be
valuable in predicting disease progression, and may represent a novel therapeutic target in
preventing or treating advanced stages of the disease.
56
Bibliography
[1] Bar-Joseph, Z., Gitter, A., Simon, I.: Studying and modelling dynamic biological pro-
cesses using time-series gene expression data. Nature Reviews Genetics 13(8), 552–564
(2012)
[2] Chiu, T.-Y., Hsu, T.-C., Yen, C.-C., Wang, J.-S.: Interpolation based consensus clus-
tering for gene expression time series. BMC bioinformatics 16(1), 1–17 (2015)
[3] Rueda, L., Bari, A.: Clustering temporal gene expression data with unequal time inter-
vals. In: Bio-Inspired Models of Network, Information and Computing Systems, 2007.
Bionetics 2007. 2nd, pp. 192–199 (2007). IEEE
[4] Ujjwal Maulik and Sanghamitra Bandyopadhyay. Performance evaluation of some clus-
tering algorithms and validity indices. IEEE Transactions on Pattern Analysis and
Machine Intelligence, 24(12):1650–1654, 2002.
[5] Subhani, N., Li, Y., Ngom, A., Rueda, L.: Alignment versus variation methods for clus-
tering microarray time-series data. In: Evolutionary Computation (CEC), 2010 IEEE
Congress On, pp. 1–8 (2010). IEEE
[6] David L Davies and Donald W Bouldin. A cluster separation measure. IEEE Transac-
tions on Pattern Analysis and Machine Intelligence, (2):224–227, 1979.
[7] Pablo A Jaskowiak, Ricardo JGB Campello, and Ivan G Costa. On the selection of
appropriate distances for gene expression data clustering. In BMC Bioinformatics,
volume 15, page S2. BioMed Central, 2014.
57
[8] Vedell, P.T., Lu, Y., Grubbs, C.J., Yin, Y., Jiang, H., Bland, K.I., Muccio, D.D.,
Cvetkovic, D., You, M., Lubet, R.: Effects on gene expression in rat liver after adminis-
tration of rxr agonists: Uab30, 4-methyl-uab30, and targretin (bexarotene). Molecular
Pharmacology 83(3), 698–708 (2013)
[9] Ferrari, D.G., De Castro, L.N.: Clustering algorithm selection by meta-learning systems:
A new distance-based problem characterization and ranking combination methods. In-
formation Sciences 301, 181–194 (2015)
[10] Chira, C., Sedano, J., Villar, J.R., Camara, M., Prieto, C.: Shape-output gene clustering
for time series microarrays. In: 10th International Conference on Soft Computing Models
in Industrial and Environmental Applications, pp. 241–250 (2015). Springer
[11] McKinley, S., Levine, M.: Cubic spline interpolation. College of the Redwoods 45(1),
1049–1060 (1998)
[12] Pamula, R., Deka, J.K., Nandi, S.: An outlier detection method based on clustering. In:
Emerging Applications of Information Technology (EAIT), 2011 Second International
Conference On, pp. 253–256 (2011). IEEE
[13] Marghny, M., Taloba, A.I.: Outlier detection using improved genetic k-means. arXiv
preprint arXiv:1402.6859 (2014)
[14] Abedalrhman Alkhateeb and Luis Rueda. Zseq: An approach for preprocessing next-
generation sequencing data. Journal of Computational Biology, 24(8):746–755, 2017.
[15] Qi Long, Jianpeng Xu, Adeboye O Osunkoya, Soma Sannigrahi, Brent A Johnson, Wei
Zhou, Theresa Gillespie, Jong Y Park, Robert K Nam, Linda Sugar, et al. Global
transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers
of disease recurrence. Cancer research, 74(12):3228–3237, 2014.
[16] Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D.R., Pimentel, H.,
Salzberg, S.L., Rinn, J.L., Pachter, L.: Differential gene and transcript expression anal-
58
ysis of rna-seq experiments with tophat and cuﬄinks. Nature protocols 7(3), 562–578
(2012)
[17] Alexander Dobin, Carrie A Davis, Felix Schlesinger, Jorg Drenkow, Chris Zaleski, Sonali
Jha, Philippe Batut, Mark Chaisson, and Thomas R Gingeras. Star: ultrafast universal
rna-seq aligner. Bioinformatics, 29(1):15–21, 2013.
[18] Society, A.C.: American Cancer Society. How is prostate cancer staged. http://www.
cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-staging.
[Online; Last accessed June 2015] (2015)
[19] Bo Li and Colin N Dewey. Rsem: accurate transcript quantification from rna-seq data
with or without a reference genome. BMC bioinformatics, 12(1):323, 2011.
[20] Williams, K., Ghosh, R., Giridhar, P.V., Gu, G., Case, T., Belcher, S.M., Kasper,
S.: Inhibition of stathmin1 accelerates the metastatic process. Cancer research 72(20),
5407–5417 (2012)
[21] Gu, Y., Chen, T., Meng, Z., Gan, Y., Xu, X., Lou, G., Li, H., Gan, X., Zhou, H., Tang,
J., et al.: Camkii γ, a critical regulator of cml stem/progenitor cells, is a target of the
natural product berbamine. Blood 120(24), 4829–4839 (2012)
[22] Meng, Z., Li, T., Ma, X., Wang, X., Van Ness, C., Gan, Y., Zhou, H., Tang, J., Lou,
G., Wang, Y., et al.: Berbamine inhibits the growth of liver cancer cells and cancer-
initiating cells by targeting ca2+/calmodulin-dependent protein kinase ii. Molecular
cancer therapeutics 12(10), 2067–2077 (2013)
[23] Chai, S., Qian, Y., Tang, J., Liang, Z., Zhang, M., Si, J., Li, X., Huang, W., Xu, R.,
Wang, K.: Ca 2+/calmodulin-dependent protein kinase iiγ, a critical mediator of the
nf-κb network, is a novel therapeutic target in non-small cell lung cancer. Cancer letters
344(1), 119–128 (2014)
59
[24] Chen, F., Wang, M., Bai, J., Liu, Q., Xi, Y., Li, W., Zheng, J.: Role of runx3 in
suppressing metastasis and angiogenesis of human prostate cancer. PloS one 9(1), 86917
(2014)
[25] Xuan, J.W., Chin, J.L., Guo, Y., Chambers, A.F., Finkelman, M.A., Clarke, M.W.:
Alternative splicing of psp94 (prostatic secretory protein of 94 amino acids) mrna in
prostate tissue. Oncogene 11(6), 1041–1047 (1995)
[26] Sasaki, T., Matsumoto, N., Jinno, Y., Niikawa, N., Sakai, H., Kanetake, H., Saito, Y.:
Assignment of the human β-microseminoprotein gene (msmb) to chromosome 10q11. 2.
Cytogenetic and Genome Research 72(2-3), 177–178 (1996)
[27] Sutcliffe, S., De Marzo, A.M., Sfanos, K.S., Laurence, M.: Msmb variation and prostate
cancer risk: clues towards a possible fungal etiology. The Prostate 74(6), 569–578 (2014)
[28] Oleksowicz, L., Liu, Y., Bracken, R.B., Gaitonde, K., Burke, B., Succop, P., Levin, L.,
Dong, Z., Lu, S.: Secretory phospholipase a2-iia is a target gene of the her/her2-elicited
pathway and a potential plasma biomarker for poor prognosis of prostate cancer. The
Prostate 72(10), 1140–1149 (2012)
[29] Fijneman, R.J., Bade, L.K., Peham, J.R., van de Wiel, M.A., van Hinsbergh, V.W.,
Meijer, G.A., O’Sullivan, M.G., Cormier, R.T.: Pla2g2a attenuates colon tumorigenesis
in azoxymethane-treated c57bl/6 mice; expression studies reveal pla2g2a target genes
and pathways. Analytical Cellular Pathology 31(5), 345–356 (2009)
[30] Shiv K Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert,
and Matthias Scherf. Prostate cancer gene profiles and methods of using the same,
November 10 2016. US Patent App. 15/108,909.
[31] Wei Gao, Jacky Wei Kei Lam, John Zeng-Hong Li, Si-Qi Chen, Raymond King-Yin
Tsang, Jimmy Yu-Wai Chan, and Thian-Sze Wong. Microrna-138-5p controls sensitiv-
ity of nasopharyngeal carcinoma to radiation by targeting eif4ebp1. Oncology reports,
37(2):913–920, 2017.
60
[32] Rotunno, M., Hu, N., Su, H., Wang, C., Goldstein, A. M., Bergen, A. W., & Shih, J.
(2011). A gene expression signature from peripheral whole blood for stage I lung ade-
nocarcinoma. Cancer Prev Res October 1 2011 (4) (10) 1599-1608; DOI: 10.1158/1940-
6207.CAPR-10-0170
[33] Ruan, H.-Y., Yang, C., Tao, X.-M., He, J., Wang, T., Wang, H.,& Qin, W.-X. (2017).
Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepato-
cellular carcinoma. American Journal of Cancer Research, 7(3), 543–553.
[34] Sayagues JM, Fontanillo C, Abad MD, et al. Mapping of genetic abnormalities of
primary tumours from metastatic CRC by high-resolution SNP arrays. PLoS ONE.
2010;5:e13752.
[35] Wang, Y., Wan, F., Chang, K., Lu, X., Dai, B., & Ye, D. (2017). NUDT expression is
predictive of prognosis in patients with clear cell renal cell carcinoma. Oncology letters,
14(5), 6121-6128.
[36] Yoo, S. S., Hong, M. J., Lee, J. H., Choi, J. E., Lee, S. Y., Lee, J., & Cho, S. (2017).
Association between polymorphisms in microRNA target sites and survival in early-stage
non-small cell lung cancer. Thoracic cancer, 8(6), 682-686.
61
Chapter 4
Machine learning approaches for
breast cancer data analysis
In this chapter, we propose three models to analyze breast cancer outcomes: a supervised
model to find indicators for breast cancer subtypes and two methods to analyze breast cancer
survivability –where the first model is supervised while the other one is unsupervised model.
The unsupervised model is the extension of our proposed method presented in Chapter 3.
4.1 Supervised Hierarchical model to Analyze Breast Cancer Data
Breast cancer is a widespread cancer type in females and accounts for many cancer cases
and cancer deaths in the world. Identifying the type of breast cancer increases the chances
of survivability. In this section, two hierarchical models are proposed, where the first one
is used to predict the breast cancer subtype, and the second is to find marker genes that
guide the treatment type throughout survivability. Suitable filter feature selection methods
and new hybrid feature selection techniques are utilized in our models to find discriminative
genes.
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4.1.1 Hierarchical supervised model for predicting breast cancer subtypes
Predicting the breast cancer subtypes is a multi-class classification problem. Machine learn-
ing methods have been used for predicting breast cancer subtypes [1], [2], [3].
In [3], Rezaeian et al. proposed a new hierarchical model to predict breast cancer subtypes.
They used Chi-square feature selection method to find informative genes in their model,
which consists of four steps. In each step, one subtype is predicted. In the first step, Basal is
predicted versus Her2, LumA, LumB, and Normal. The dataset is divided into two classes,
one for Basal and another class for the remaining three subtypes and Normal. Chi-square
feature selection is applied to find a suitable subset of genes for predicting Basal against
the remaining four classes. Then the SVM-L classifier is utilized for identifying the type of
instances. If an instance is not classified as Basal, the sample goes to the second step. In
the second step, Normal instances are classified versus Her2, LumA, and LumB in the same
way. Her2 subtype is identified against LumA and LumB subtypes in the third step. Finally,
LumA subtype is separated from LumB.
4.1.2 Methods
The framework of the proposed model consists of four steps. In each step, one subtype is
predicted. Each step consists of two phases: feature selection and classification. In the first
phase, a discriminative subset of genes is selected based on the subtype which is going to
be predicted in that step. In the second phase, a suitable classifier is utilized to identify the
type of an unknown instance.
The feature selection algorithms and the classifiers used in our method are presented as
follows:
Feature selection methods
Each instance in the breast cancer dataset consists of 13,582 genes. As shown later, all these
features are not informative for recognizing the breast cancer subtypes. As a result, feature
selection methods are used to find a suitable subset of genes in each step. In this model,
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different filter methods such as Information Gain (IG) [5], Chi-square [6], and Symmetrical
Uncertainty (SU) [7] are utilized in each step. We also propose new hybrid methods for
finding an optimal subset of genes.
Classification methods
SVM, Na¨ıve Bayes [8], random forest [21], and k-nearest neighbor (k-NN) classifiers have
been used in the literature [4], [10], [11], [12], [13], [14], [15]. In [16], SVM-L has been utilized
to predict the breast cancer subtypes. In this model, different classifiers are used to predict
subtypes in each step. Moreover, in the first and third steps of the proposed method, more
than one classifier such as SVM-L, SVM with polynomial kernel (SVM-P), SVM with Radial
Basis Function kernel (SVM-RBF), Sequential Minimal Optimization (SMO), and Random
Forest classifiers were used.
4.1.3 Results and experiments
In this section, we compare our model with existing work. To compare the performance of the
proposed model and SVM-RBF, we applied SVM-RBF without using any feature selection
algorithms and with Chi2 and IG methods on the breast cancer dataset. The results along
with the results of the proposed method are reported in Table 4.1. As shown in Table 4.1,
the proposed method achieves 100% accuracy which is 14.4% higher than the best accuracy
reported for SVM-RBF in Table 4.2 shows the result in each step in the tree model.
Table 4.1: Comparison of the proposed model with SVM-RBF and an existing model.
Model Feature Selection Genes# A% P R FM
SVM-RBF - All 77.85 % 0.802 0.778 0.749
SVM-RBF Chi2 20 86.71% 0.866 0.867 0.864
SVM-RBF IG 20 87.34% 0.872 0.873 0.872
Rezaeian et al [4] Chi2 18 95.11% 0.951 0.951 0.951
Proposed Proposed 18 100% 1.000 1.000 1.000
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Table 4.2: The Steps of the proposed model shows the biomarker genes and which class can be determined
at each step.
Step Biomarker genes Accuracy Classes
Step 1 AGR2, and TFF3 100% Basel vs the
rest
Step2 HMGCS1, YBX1, C15orf39, HDAC11, and CTSF 100% Her2 vs the
rest
Step3 CX3CL1, and ARAP3 100% Normal vs
the rest
Step 4 SPAG5, BUB1, MRPS23, CDKN3, ZFP36L2,
CENPL, BOLA3, COX4NB, RNF2
100% LumbA vs
LumbB
4.1.4 Discussion
Among the genes that have been identified by our proposed method for subtype classifica-
tion and identification, several genes have been found to be involved in breast cancer. For
example, AGR2 is shown to be a promising drug target in breast cancer and can be served
as a useful prognostic indicator and biomarker in breast cancer metastasis [17]. TFF3 is also
a valuable predictive biomarker of endocrine response in metastatic breast cancer [18] [19].
YBX1 has been shown to have an important role in controlling MDR1 gene transcription,
which can provide a basis for the analysis of molecular mechanisms that are responsible for
intrinsic multi-drug resistance in breast cancer [20]. HDAC11 has been shown to play an
important role in cancer cell survival and may represent a novel drug target in oncology [21].
Moreover, it has been shown that the high expression of SPAG5 in tumour cells correlates
with aggressive tumours in breast cancer [22]. BUB1 plays an important role in breast
cancer proliferation and progression, and nuclear BUB1 immunohistochemical status has
been considered as a potential prognostic factor in patients with breast cancer [23]. Also,
dynamic changes in CDKN3 gene expression can predict prognosis of those breast cancer
patients that have been treated with tamoxifen [24]. Finally, gene ZFP36L2 has been shown
to be Estrogen Receptor β (ERβ) regulated in T47D breast cancer cell line [25].
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4.2 Hierarchical prediction model for treatments through out sur-
vivability
Although with the fast increase in breast cancer rates nowadays, the survival rates are also
increased not only due to the improvement in treatments, but also because of the new
technologies and enhanced research [26]. Breast cancer is still one of the leading causes of
women death worldwide. The survival rates vary with the treatment therapy, which includes
Surgery, Chemotherapy, Hormone therapy, and Radiotherapy. Patient response to treatment
varies from one patient to another [27]. Traditional laboratory techniques such as CAT scan
and Magnetic Resonance Imaging (MRI) provide useful but very little information, and
with the advances in DNA microarray technology which provide high throughput samples
of gene expression. Analyzing gene expression from breast cancer patients who undergo
different treatments provides a better understanding of the disease progression. A large
number of features complicates the computational model, and since it is much higher than
the number of samples, it creates a problem known as the curse of dimensionality, where
the standard classifiers struggle to handle the volume of features, and the model overfits
the data. Therefore, feature selection techniques are applied to solve the problem and filter
out irrelevant features. Mangasarian et al. utilized a linear SVM to extract six features
out of 31 clinical features; the data set contains samples from 253 breast cancer patients.
The model classified the samples into two groups. Node-positive in which the patients have
some metastasized lymph nodes, and node-negative for patients with no metastasized lymph
nodes. The six features were then used by a Gaussian SVM classifier to classify the patient
into three prognostic groups: negative, middle, positive. They found that patients in the
negative group had the highest survivability among the other groups, with the majority
of them having received chemotherapy as a treatment [28]. Using samples from patients
with high-risk clinical features in early stages of breast cancer, Cardoso et al. proposed a
statistical model to decide the necessity of chemotherapy treatment intervene from not based
on the expression of the gene [29]. In earlier work, we built a prediction model for survival
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based on different treatments without defining the period of survivability [30]; that is, given
a training set consisting of gene expression data of breast cancer patients who survived or
died after receiving a treatment therapy, we built a classifier model which predicted whether
a new patient survive or die. In this paper, we propose a classifier model to predict which
BC patient will survive beyond five years after undergoing a given treatment therapy. The
classifier model is built on top of a feature selection model, which identifies the genes which
can best distinguish among the survival classes.
4.2.1 Materials and methods
Samples from a publicly accessible dataset of 2,433 breast cancer patients and survival is
used to validate this approach [31]. After studying the given data, a set of six classes were
identified as the base of this work; these classes are the combination of each treatment
(Surgery, Hormone therapy, and Radiotherapy) with a patient statue (Living or Deceased).
The number of samples (patients) for each class are shown in Table 4.3, which indicates that
a total of 347 patients are used in this work.
Table 4.3: Class list with the number of saples in each class
Class Number of sam-
ples
Living and Radio (LR) 132
Deceased and Radio (DR) 19
Living and Hormone (LH) 20
Deceased and Hormone (DH) 6
Living and Surgery (LS) 130
Deceased and Surgery (DS) 40
Total 347
Based on the available data, only three treatment therapies are covered which are Surgery,
Hormone therapy, Radiotherapy. Our proposed model is a hierarchical classifier that classifies
one versus the rest classes. The dataset contains unbalanced classes, a problem that is well-
known in machine learning. The pipeline starts with feature selection methods that include
Chi-square and Information Gain, which are applied for limiting the significant number
of features (genes). A wrapper method is also used to obtain the best subset of genes that
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represent the model by utilizing the minimum redundancy maximum relevance (mRMR) [32]
feature selection method. This step is followed by applying several class balancing techniques
such as SMOTE [33], cost-sensitive [34], and resampling [35] to balance the number of classes
before applying different types of classifiers such as Naive Bayes and Random forest. Finally,
a small subset of biomarker genes are recognized for predicting the proper treatment therapy.
To the best of our awareness, this work is the first prediction model which is built on the
combination of treatment and survivability of the patient as a class.
Multi-class classification model
We applied a multi-class approach, the one-versus-rest technique. This approach assumes
that one class is classified against the rest of classes, and then removed from the dataset.
Afterwards, we select another class to classify it against the rest and so on. Using a greedy
method to find the starting node, the method classifies all possible combinations such as ‘DH’
against the rest, then ‘DR’ against the rest, and so on for all the six classes. Afterwards,
the best starting node is selected as the root node of the classification tree based on the best
performance. Several classifiers were utilized to achieve these results such as random forest
and Naive Bayes. The classification model was built and tested with 10-fold cross-validation.
4.2.2 Results and discussion
The model of the multi-class is shown in Figure 4.1, which shows the final results for each
node and the performance measures that were considered such as accuracy, sensitivity, F1-
measure and specificity. The figure also shows the number of the correctly and incorrectly
classified instances in each node.
Moreover, Figure 4.1 also shows that the root node, DH against the rest, yields 100%
accuracy. The second node is obtained after removing the ‘DH’ instances from the data set
and then classifying each class against the rest. The best outcome was ’DR’ with accuracy
of 100%. We repeat the same process for the third node, finishing with ‘LH’ with accuracy
of 100%. Then, ‘DS’ in the fourth node with accuracy of 97.9%, sensitivity of 96.9%, and
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DH VS 
Rest
Accuracy 100%
Specificity 100%
Sensitivity 100%
F-Measure 100%
Correctly Classified 6
Incorrectly Classified 0
DR VS 
Rest
Accuracy 100 %
Specificity 100 %
Sensitivity 100%
F-Measure 100 %
Correctly Classified 19
Incorrectly Classified 0
LH VS 
Rest
Accuracy 100 %
Specificity 100 %
Sensitivity 100%
F-Measure 100 %
Correctly Classified 20
Incorrectly Classified 0
DS VS 
Rest
Accuracy 97.9%
Specificity 100%
Sensitivity 96.9%
F-Measure 98.5%
Correctly Classified 40
Incorrectly Classified 0
LR VS 
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Accuracy 80.9%
Specificity 76.9 %
Sensitivity 84.8 %
F-Measure 81.8 %
Correctly Classified 112
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Figure 4.1: Multi-Class classification model with performance measures.
specificity of 100%, because all the ‘DS’ samples were correctly classified. In the fifth node, we
classify ‘LR’ and ’LS’; the accuracy drops down to 80.9%, because it is difficult to distinguish
between the living samples in both of them.
Overall, our method identified 47 gene biomarkers listed in Figure 4.1; a functional vali-
dation and biological insights were done for some of the genes by studying the information
provided in the literature and their relation to breast cancer.
Figure 4.2 shows that the gene expression of AKIP1 is up-regulated in the ‘DH’ samples
compared to the rest of the samples, while it shows that gene ASAP1 is down-regulated
in the ‘DR’ samples compared to the rest of the samples. ASAP1 has been reported to
be a breast cancer biomarker; it is precisely correlated with the invasive phenotypes that
have not been identified accurately [36]. Sabe et al. reported that ASAP1 is abnormally
over-expressed in some breast cancers and used for their invasion and metastasis.
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Figure 4.2: Box plots for the AKIP1 and ASAP1 genes in node number one and two, which show the mini-
mum, first quartile, median, third quartile, and maximum gene expression values for each group of samples
(‘DH’ vs. Rest) and (‘DR’ vs. Rest).
4.3 An adaptive clustering algorithm for gene expression time-
series data analysis
Cancer is characterized by uncontrolled cell-growth in an organ. It starts when there is
an unpredictable change in the structure of DNA in a cell that creates a mutation. These
mutated cells divide out of control and crowd out the healthy cells in the body. Breast
cancer refers to a malignant tumor that has originated from the cells of the breast. It is
the most common female cancer in the Western world and one of the leading causes of
death by cancer among women. It stands second among the most prominent causes of death
amongst the middle-aged women in the world and most common in women over 50 years of
age [37–40]. Mutations in a small number of genes, oncogenes or tumor suppressors, whose
change deregulate many biological processes leads to initiation and progression of breast
cancer as well as resistance to treatment [41]. The biomarker is defined as a measurable
indicator of a biological process. The discovery of biomarkers can be a crucial step in
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Figure 4.3: Circos plot for the biomarker genes in node number one for the Rest samples based on the
correlation coefficient among genes expressions (p < 0.05).
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predicting survivability and handling of any disease. Gene expression values are different in
various stages of progression of the disease. One of the most powerful applications of gene
expression analysis is to identify biomarkers that can be used for disease risk assessment,
early detection, prognosis and preventive measures [42]. Genes tend to under-express or over-
express during progression and recurrence of any disease, especially cancer. The problem of
choosing those biomarker genes that provide insights about the disease poses a challenging
problem in high-dimensional data.
Clustering time-series methods have been used in bioinformatics mainly for gene expres-
sion profiles [43, 44]. Rueda et al. proposed a clustering method that, first, aligns the gene
expression profiles together to minimize the total area between the gene profiles, and then
cluster the profile using an agglomerative clustering method based on the furthest-neighbor
distance between each pair of clusters as in Chapter 3. Also, they used a modified version
of I-index to validate the optimum number of clusters.
In this section, we propose two methods to identify the genes that are dissimilar, as outlier
genes that could serve as potential biomarkers. Outliers can be of two types, local outliers
and global outliers. Figure 4.4 depicts global and local outliers. Let us consider the curves
in Figure 4.4 as gene expression profiles. From the beginning, the curve in red clearly trends
different from other curves. Thus, this is a global outlier. The curve in yellow follows a
similar trend with other curves up to a certain point (represented by dotted lines) and starts
following a different trend. This is called a local outlier.
The local and global outlier genes could serve as potential biomarkers since they follow a
different trend than the other genes in the background, which may give a biological insight
of the relationship between those abnormal expressions of the outliers and breast cancer
progression.
4.3.1 Data pre-processing
For this work, we have used the METABRIC dataset, which is publicly available at cBio-
Portal. This dataset contains clinical data (Patient ID, survival status, overall survival in
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Figure 4.4: Local and global outliers.
months and type of treatment) for a total of 1,904 patients. Of these, 480 patients were
diagnosed/treated for breast cancer but died because of some other reason; thus, we filtered
them out as they will have no relevance to our problem of predicting biomarkers of surviv-
ability. That gives us a total of 1,424 patients; from which we consider only the patients
who are still living and disease free, 801 patients, to predict biomarkers of survivability. The
dataset also has expression data (24,368 genes determined through microarray) for all the
patients in the clinical dataset.
This work, to the best of our knowledge, is the first to assume that, overall survival of
cancer patients are time points to approximate disease progression. This assumption is based
on the fact that any biological function is a continuous process and breast cancer is not an
exception. Previous work on detecting biomarkers at a gene level was focused on grouping
up of similar gene expression profiles and eliminating the outlier genes as noise.
First, the two datasets (clinical dataset and the gene expression dataset) were merged with
the KEY = PATIENT-ID, and next, we create a time-series. A time-series is a sequence
of measures at specific time points. Gene expression of cancer patients can be measured at
different time points. Also, time points can be interpolated to approximate the growth of
disease over time and isolate outliers.
Figure 4.5 depicts the process by which our time series data were created. The dataset
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Figure 4.5: Dataset pre-processing.
has patients overall survival (the day patients were diagnosed with breast cancer to the day
the dataset was created) in months. In this work, we assume that the survival periods of each
patient as time-series bins. The shortest time of patient who survived is one month and the
longest being 342. To create the time-series data, we partition the time axis into survival
bins of length six months. We chose an interval of 6 months since the average time for
progression of cancer is six months. Also, for a cancer patient who is undergoing treatment,
it takes at least 3-6 months to respond to it. For the dataset we have, time series starts
from 1-6 months, 7-12 months and go on until 337-342, giving us 55 time points. Next, we
average the gene expression levels over all the patients appearing in a survival bin.
4.3.2 Methods
After creating the time-series dataset, we approximate the progression of each gene expres-
sions throughout 55 time points using cubic spline interpolation. After universally aligning
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gene expression profiles, we clustered them using an agglomerative clustering approach based
on the area between the profiles as a distance measurement.
Natural cubic spline interpolation and universal alignment of gene profiles
Gene expressions throughout the time points are natural cubic spline interpolated to create
a trending profile for each gene in the given dataset. Then, the profiles were universally
aligned by shifting the interpolated gene profiles vertically in such a way that the squared
error between any two of those profiles is minimal as mentioned earlier in Chapter 3.
Clustering algorithm
The main objective of using clustering here is to filter out the profiles that trend differently
from other profiles [45–47]. In this work, we have chosen singleton clusters as outliers. We
also choose clusters with a very small number of profiles that follow the same trend with
profiles within the cluster and dissimilar from other profiles in a different cluster. Hierarchical
agglomerative clustering is a bottom-up approach. Initially, each profile in the dataset is
an individual cluster (each profile is a cluster), and then the clusters are merged based on
the distance between them. Here, the clusters are combined based on the complete linkage
criteria (computing the distance between the furthest pair of points for each pair of clusters
and combines the pair of clusters that has the minimum furthest distance among all such
distances). The merging process continues until the desired number of clusters is reached.
This approach places the profiles with similar trends into one cluster and filters out profiles
that are less similar to other profiles as one or more different clusters.
Profile alignment and agglomerative clustering index
Profile alignment and agglomerative clustering Index (PAAC) is the validity index that has
been used to determine the desired number of clusters for the dataset. PAAC is a modified
version of the I-index. IPAAC index is the modified version of the I-index formula to reduce
the impact the I-index value faces when many clusters are used in it as follows:
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I(k) = (
1
k
)q × ( B
W
×D)p,
where:
D = (maxi,j=1)
kd(µi, µj),
B =
k∑
i<c
d(µi, µc),
W =
k∑
i=1
n∑
j=1
µijd(xj, µi)
k is the number of clusters, q is the coefficient of normalizing the number of clusters, p is
the coefficient of the degree of the index, µij = 1 if gene j belongs to the i
th cluster; otherwise
µij = 0, µi is the center of i
th cluster, n is the number of genes, and d(., .) is the distance
between the profiles. The aim here is to choose the value of k, that has the maximum value
of I-index as the desired number of clusters for the dataset.
Baseline method
In our baseline method, the entire time-series dataset (time point 1 to time point 55) is
universally aligned towards the universal profile z(t). Then, we use hierarchical clustering
to detect the gene profiles that trend differently from others. Finally, we use cubic spline
interpolation to identify singleton clusters that trend differently from other genes as outliers.
Figure 4.6 depicts the work flow of our baseline method.
Adaptive clustering algorithm
We propose an iterative adaptive clustering algorithm (ACTS) wherein we slice the time-axis
into distinct intervals based on three parameters, window size, outlier threshold and step size
as seen in Figure 4.3.2. To detect the local outliers, it is essential to slice the time-series data
and perform the clustering algorithm on each interval separately and identify the outliers
based on the partial clustering results. Partially clustering the dataset makes our algorithm
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Figure 4.6: Work flow of baseline method.
Figure 4.7: Slicing the time series based on window size and step size.
to adapt to the structure of data in a specific interval and identifies the genes that are more
relevant to breast cancer survivability.
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Figure 4.8: Window size and step size.
Window size for the first iteration
Window size for the first iteration/interval is decided based on visualizing the data. This
parameter is dynamic and highly dependent on the structure of the dataset. We choose
the window size in such a way that the interval has considerable gene expression variability
among the genes and, many visible peaks which could be potential outliers. A disease like
cancer during the progression has several genes that are over-expressed in the initial stage
of the disease. Thus, the main idea here is to pick many observations/genes that trend
differently from others in the first Iteration. Once we determine the window size for the first
iteration, the algorithm proceeds as follows:
• Extract data based on the window size from the time-series dataset.
• Perform multiple profile alignment and clustering to detect potential biomarkers within
that interval. In Figure 4.8, based on visualization, we choose window size = 8 time
points for the first iteration in our time-series dataset.
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Figure 4.9: Change in gene trend.
Step size = 2
Step size here is a fixed parameter and is used from the second iteration onwards until the
last time-point in the dataset. Genes that are outliers trend differently from others. We
investigated all possible trends which a gene could follow, to be captured as an outlier.
In Figure 4.9, the lines colored in red depict all possible trends a gene could follow during
progression. Based on this observation, we need to identify the trend of a gene in at least two
time points to determine if it is an outlier in an interval. From the second iteration onwards,
the step size is used to include new time-points from the dataset for the next consecutive
iterations until the last time-point is reached. After the first iteration, we proceed with
the algorithm based on step size = 2. Figure 4.8 also depicts how step size is used in our
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time-series dataset. From the second iteration until the end, the algorithm proceeds as
follows:
• Adds two points after each iteration until the last time-point in the dataset.
• Performs multiple profile alignment and clustering on each interval until the end.
Outlier threshold
Outlier threshold is an arbitrary parameter used to determine and limit the number of genes
in a cluster that can be filtered out as outliers. Alkhateeb et al. used a threshold of one gene
in a cluster (singleton clusters) [45]. In our case, it is difficult to determine the local outliers
with a threshold of one gene in a cluster. With specific time intervals, it is not easy to filter
out singleton clusters as there could be many genes following a similar trend. Thus, we set
a threshold of ≤ five genes in a cluster for filtering out the outliers and reduce redundancy
in each iteration. By grouping genes that have very high similarity (similar trends) to each
other, the algorithm ensures minimum inter-cluster dissimilarity and maximum intra-cluster
dissimilarity among the clustered data.
Workflow of proposed algorithm
Figure 4.10 depicts the work flow of the proposed algorithm. The proposed algorithm uses
an iterative approach to detect outliers as biomarkers. We first slice the time-series dataset
based on two parameters, window size and step size. Window size is chosen in a way that
covers the interval that has the largest variation among genes. Step size here is a fixed
parameter, which is equal to two. Outlier threshold is an arbitrary parameter used to
limit the number of outliers in each interval. Then, we use hierarchical clustering and spline
interpolation methods to detect outliers on each sliced interval based on an outlier threshold.
Algorithm 1 is the pseudo code for the ACTS.
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Figure 4.10: Workflow of ACTS
Algorithm 1 ACTS pseudocode.
Input: Time-Series Dataset,Window size, Step size, Outlier Threshold, k range
Output: Outliers in each interval
1: input1 = Time-series Dataset (1:Windowsize)
2: clustering and PAAC(input1)
3: repeat
4: input2 = new dataset;
5: clustering and PAAC(input2)
6: until last time point is reached
7: function clustering and PAAC(input)
8: for each gene in input do
9: uni-align = Align each gene towards universal profile z(t)
10: end for
11: for each value in k range do
12: perform Hierarchical Agglomerative Clustering of uni-align
13: perform PAAC to determine the best k value
14: end for
15: Choose k value for max(PAAC)
16: plot cubic spline Interpolation for best k value clustering result
17: if Cluster size ≤ OutlierThreshold then
18: filter genes in cluster as outliers
19: else
20: new dataset = Add time-points based on Stepsize for next iteration.
21: end if
22: end function
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4.3.3 Comparison with other methods
We tried to utilize a bi-clustering method called BiGGEsTS [100, 101], which created
679,107 bi-clusters for our time-series dataset. The tool did not detect any outliers and
is not flexible enough to let us download the data created in each bi-cluster. We had to
visually check the bi-cluster to compare the outlier genes from ACTS.
4.3.4 Results
With parameters q = 0.7, p = 2, k = 46 clusters, our baseline method detected 24 local
outliers (as singleton clusters) of which 14 genes were related to breast cancer survivability.
ACTS with parameters, window size for interval-1 set to 8, step size set to 2 from interval-2
onwards, outliers threshold on each interval ≤ 5, detected 53 outliers. Out of 53, 46 of them
were related to breast cancer. ACTS yields an accuracy of 86.7% in terms of clustering the
potential biomarkers of breast cancer survivability. We identified 24 oncogenes and 18 tumor
suppressor genes. Table 4.4 shows the results of baseline method and Table 4.5 shows the
results of ACTS.
Biological insight
With the help of previous literature, we observe the biological significance of all genes ob-
tained as potential biomarkers of breast cancer survivability:
Baseline method
• PSAP are related to breast cancer recurrence and potentiating resistance to breast
cancer treatment [48].
• CD81 is a biomarker responsible for cancer proliferation [49].
• EEF1A1 is an oncogene, a potential oncoprotein that is over-expressed in about two-
thirds of breast tumors [50].
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Table 4.4: Result of baseline method.
S.No Gene Related to BC
1 HIST1H4C X
2 ATP5EP2 X
3 PSAP X
4 CD81 X
5 RPS5 X
6 EEF1A1 X
7 PYY2 X
8 HES7 X
9 ZNF678 X
10 ATP5B X
11 RPL11 X
12 RPS20 X
13 SNRPD2 X
14 RPL32 X
15 HSP90B1 X
16 TOMM7 X
17 UBA52 X
18 BGN X
19 RPS15 X
20 RPL12 X
21 TIMP1 X
22 RPS16 X
23 FTL X
24 RPL10 X
• HES7, SNRPD2, UBA52, RPL12 are genes that can affect the survival rate of
breast cancer patients if highly expressed [51–55].
• RPL11, TIMP1, FTL and RPL32 are biomarkers of breast cancer development
[56–58].
• HSP90B1 is an oncogene that is associated with breast cancer metastasis and decreased
survival [54].
• BGN is used for subtype-specific classification [59].
• RPS16 is MicRNa target to improve the efficacy of cancer therapy [Jezequel et al.,
2012].
• Oncogenes: SCGB2A2, ANKRD30A, SCGB1D2, SCGB2A1, TFF3, KRT81, CSN3,
KLK5, C4orf7, BEX1, UGT2B11, UGT2B7, LTF, UGT2B28, PROM1, KRT7, SER-
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PINA6, CPB1, RAMP1, CST1, FLJ23152, S100A9, S100A8 [59–78].
• Tumor Suppressor Genes: TAT, BAMBI, VTCN1, HLADRB1, PXDNL, DIO1,
HSPB8, CYP4X1, HMGCS2, CYP4Z1, TFAP2B, TFF1, GRIA2, EEF1A2, BMPR1B,
MYBPC1, SLC27A2, SERPINA5 [79–95].
• SYT13: & TUBA3D are associated with ER specific cancer [96,97].
• TCN1: Patient will have adverse effects on treatment if this gene is highly expressed [98].
• S100P: Survival rate is decreased if this gene is highly expressed [99].
• PIP:
1. regulates proliferation of luminal-A type breast cancer cells in an estrogen-independent
manner [88].
2. ER+ breast cancer, particularly those with very high level of ER expression, PIP
appears to play an important role in proliferation and invasion as well as acquired
resistance to tamoxifen [89].
3. Biomarker in breast cancer micrometastasis [90] and outcome prediction in breast
carcinoma [78].
Discussion
Figures 4.11 and 4.12 depict the heatmaps for oncogenes and tumor suppressor genes from
ACTS. Most of the oncogenes were over-expressed in the first and last few time-points. Some
tumor suppressor genes are under-expressed at the beginning, and most of them are over-
expressed at the end. The activity of tumor suppressor genes towards the end satisfies the
biological meaning of cancer, suggesting that the down-regulation of a set of genes may be
the underlying mechanism of cancer formation, while the up-regulation may characterize and
possibly control the state of evolution of individual cancers. Initially, the activity of tumor
suppressor genes was low, resulting in high activity of oncogenes, and hence the progression
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Figure 4.11: Heatmap for 24 oncogenes.
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Figure 4.12: Heatmap for 18 tumor suppressor genes.
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of the disease. Towards the end, more tumor suppressor genes are activated which neutralizes
the effect of oncogenes helping in patients increased survivability rate.
Since we know precisely at which time-point an oncogene is over-expressed, we can direct
or target treatments towards it to reduce/control their high activity which could improve
patients overall survivability. At the same time, any efforts to trigger or enhance the activity
of tumor suppressor genes could also contribute to increasing the rate of survivability during
treatment.
Conclusion and future work
We proposed an innovative approach to detect outliers (genes that trend differently from
the majority of other) as biomarkers of breast cancer survivability using a time-series model.
These biomarkers can be used to predict and improve patient survival, diagnosis, and therapy
for breast cancer. First, we created a time-series dataset using patients overall survival.
Then, we grouped patients into survival bins based on their survival in months and averaged
the gene expression level of all the patients in each survival bin. Initially, we found global
outliers using all the time points from the time-series dataset. Then, we sliced the time
series dataset with a sliding window approach to create gene-expression data on specific
intervals and used profile alignment and agglomerative clustering in each interval to detect
local outliers. Finally, we found the biological relevance of genes closely related to breast
cancer survivability suggesting them as potential indicators for wet-lab experiments. Our
algorithms detected 60 genes related to breast cancer survivability including 36 oncogenes
and 18 tumor suppressor genes. In this work, we have used the data from living patients in
the dataset. As future work, we plan to extend ACTS to the patients who died to pick more
indicators. Then, we can compare the two results (outliers from living and dead datasets)
and pull meaningful insights. We are also planning to try the same approach on a different
cancer dataset. e.g., prostate cancer data.
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Table 4.5: Results of ACTS method.
S.No Gene Related to BC
1 1..8 SCGB2A2 X
2 ANKRD30A X
3 SCGB1D2 X
4 SCGB2A1 X
5 1..10 PIP X
6 TFF3 X
7 KRT81 X
8 CSN3 X
9 KLK5 X
10 C4orf7 X
11 TAT X
12 BEX1 X
13 UGT2B11 X
14 UGT2B7 X
15 LTF X
16 UGT2B28 X
17 LOC338579 X
18 PROM1 X
19 BAMBI X
20 VTCN1 X
21 KRT7 X
22 DQ893812 X
23 HLA-DRB1 X
24 1..12 DB005376 X
25 SERPINA6 X
26 PXDNL X
27 CPB1 X
28 DIO1 X
29 HSPB8 X
30 RAMP1 X
31 CST1 X
32 FLJ23152 X
33 1..18 CYP4X1 X
34 HMGCS2 X
35 CYP4Z1 X
36 TFAP2B X
37 PPP1R1B X
38 1..20 TFF1 X
39 GRIA2 X
40 EEF1A2 X
41 BMPR1B X
42 CLIC6 X
43 1..34 TCN1 X
44 MYBPC1 X
45 CNTNAP2 X
46 S100A9 X
47 S100A8 X
48 S100P X
49 1..36 SLC27A2 X
50 PHGR1 X
51 SYT13 X
52 SERPINA5 X
53 1..50 TUBA3D X87
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Chapter 5
Transcriptomics signature from next
generation sequencing data reveals
new indicators related to prostate
cancer
Prostate cancer is one of the most common types of cancer among men worldwide. It is
estimated that more than one in 1.2 million men have been diagnosed with prostate cancer
in 2015, resulting in more than 335,000 deaths [1]. A current obstacle in improving patient
care is the inability to accurately predict tumors that are at a high risk for progression.
Identifying reliable prognostic biomarkers to guide treatment decisions is a high priority in
the prostate cancer field.
Next-generation sequencing has revolutionized genomic and transcriptomic analysis. RNA-
Seq reads the transcriptome at a single-nucleotide resolution, revealing unexplored genomic
and transcriptomic territories not revealed using conventional technologies, such as microar-
ray [2,3]. RNA-Seq represents a high-throughput technique capable of identifying nonconven-
tional biomarkers, such as noncoding RNA and alternative splicing events [2,3]. Alternative
splicing can produce protein isoforms with potentially different functions from the same
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DNA sequence. Indeed, approximately half of all active splicing events are altered in ovarian
and breast tumors [4]. RNA-Seq can also measure transcriptomic activity and transcrip-
tome assembly to provide better understanding of the regulation of corresponding protein
isoforms [5–8]. A typical RNA-Seq experiment, however, produces a large amount of data
and, therefore, demands considerable computational resources in both time and space. Using
machine learning to analyze RNA-Seq data can reduce redundant and irrelevant information
while providing a selection of potentially significant biomarkers for biological validation. Op-
timizing a computational approach to effectively isolate novel splice variants from RNA-Seq
data may provide invaluable clues about novel biomarkers for detecting and predicting the
progression of prostate cancer. Several studies have used RNA-Seq to identify new potential
biomarkers for prostate cancer. Feng et al. presented a comprehensive review of the most
recent studies on alternative splicing in cancer using RNA-Seq data [9]. This included an
overview of several publicly available RNA-Seq datasets and the most recent open-source
bioinformatics tools for RNA-Seq data analysis. Recent studies using RNA-Seq for prostate
cancer analysis include genome-wide association and variation studies, non-coding RNAs
(e.g., microRNA, lincRNA and siRNA), somatic mutations, chimeric RNA and gene fusion.
Kannan et al. used RNA-Seq on 20 human prostate cancer and 10 matched benign prostate
tissues from patients who had received no preoperative therapy prior to radical prostatec-
tomy and identified a potential link between increased chimeric RNA events and prostate
cancer [10]. Pflueger et al. used RNA-Seq data from 25 human prostate cancer samples
and isolated 7 novel gene fusions related to prostate cancer, including TMPRSS2-ERG [11].
TMPRSS2-ERG gene fusion is present in 50–90% of human prostate cancers and has been
identified as an early molecular event associated with invasion of the disease [12]. Ren et
al. also identified recurrent gene fusions in 14 primary prostate tumors from a Chinese pop-
ulation found TRMPRSS2-ERG fusion to occur at a very low frequency but isolated two
novel gene fusions, CTAGE5-KHDRBS3 and USP9Y-TTTY15, that occurred frequently in
the Chinese cohort. These conflicting reports illustrate that disparity exists among prostate
cancer patients of different ethnic backgrounds In another study [13], Xu et al. identified
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92 new genes with somatic mutations in human prostate cancer study used RNA-Seq data
from five cancer patients to detect variants of chromosomal rearrangements, insertions and
deletions of significance [14], they identified a frame-shift mutation in the coding region of
TNFSF10 that disrupts its ability to induce apoptosis, a change that may promote tumor
progression. Prensner et al. focused on new noncoding RNA and found an unannotated lin-
cRNA, PCAT-1, a prostate-specific regulator of cell proliferation [15]. Exploiting the high-
resolution features of RNA-Seq that allow for reconstructing the transcriptome, inferring
protein isoforms and the corresponding protein function can offer an integrative approach to
better understanding the onset and progression of disease. Thus, in this study, we propose
a new model for detecting differential splice junctions in prostate cancer using RNA-Seq
data. This model identifies transcripts associated with malignant tumors as compared to
corresponding matched normal samples and transcripts that are differentially expressed dur-
ing the disease progression. Our analysis revealed several transcripts that can be used as
potential biomarkers for predicting prostate cancer and disease progression.
5.1 Materials
We used three datasets, Kim’s [16] Ren’s [13], and Kannan’s [10] each containing matched
normal versus malignant prostate cancer tumor samples. Ren’s dataset used random hex-
amer primers, while the other datasets used oligo (DT) primers. All these datasets are in
sequence read archive (SRA) file format and are publicly available from the national center
for biotechnology information (NCBI) repository. Table 1 shows the number of samples in
each dataset.
In addition, we used the dataset from Long et al. [17], which contains prostate cancer
progression stages using 104 samples from 100 patients. Table 5.1 shows the distribution of
samples across various stages of prostate cancer in this dataset.
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5.2 Methods
5.2.1 Genome mapping and transcriptome assembly
Figure 5.1 shows the pipeline of our proposed model. Initially, samples are pre-processed
individually by mapping the mRNA reads of each sample to the Human Genome (hg19)
using Tophat2 [18] and Bowtie2 [19], two fast methods for mapping splice junctions and
aligning short reads, respectively. In the next step, we use Cuﬄinks [6] for assembling the
transcriptome using the mapped reads from the previous step based on RefSeq annotation
[20]. Cuﬄinks computes all transcript abundances in terms of FPKM values (fragments per
kilobase of exon per million of mapped reads) for each transcript in each of the samples.
Both Tophat2 and Cuﬄinks were run using default parameters.
5.2.2 Finding differentially expressed transcripts
The deliverables of our study two-fold. First, we aim to identify a gene signature that predicts
prostate cancer by comparing cancer versus their matched normal counterparts. Secondly,
we focus on differential expression of gene transcripts in a pairwise analysis of various stages
of prostate cancer progression. Using the latter, we anticipate that this type of analysis will
reveal gene transcripts that are potential markers for prediction of disease progression.
Table 5.1: Datasets used in this study for malignant vs. normal analysis with the number of samples in each
dataset.
Dataset # of Tumor Sam-
ples
Reference
Malignant Matched
Normal
Kim 7 4 [17]
Ren 14 14 [13]
Kannan 10 10 [10]
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Figure 5.1: - A Schematic view of the proposed workflow for finding differential transcripts between benign
vs. malignant and across various stages of prostate cancer
Normal versus malignant
We consider the identification of differentially expressed transcripts in normal versus malig-
nant prostate cells as a two-class classification problem, where each transcript is used as a
feature along with FPKM as feature value. After obtaining the transcripts using cuﬄinks,
Table 5.2: Distribution of Long’s dataset samples in various stages of prostate cancer.
Prostate
stage
Description # Patients
T1c The tumour is not detectable via imaging techniques, but it is detectable
using a needle biopsy performed due to an elevated serum PSA
14
T2 The tumour is palpable, but confined to the prostate 10
T2a The tumour is in half, or less than half, of one of the prostate glands two
lobes
23
T2b The tumour is in more than half of one lobe, but is not in both lobes 11
T2c The tumour is in both lobes but confined within the prostatic capsule 30
T3 The tumour start spreading out of the prostate tissue 2
T3a The tumour has spread through the prostatic capsule on one or both sides,
but has not spread to the seminal vesicles
6
T3b The tumour has invaded one or both of the seminal vesicles 8
T4 The tumour rises to other organs 1
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we used minimum Redundancy Maximum Relevance (mRMR), which is a greedy feature
selection method that incorporates a classifier to find a subset of features that accurately
classify the samples. After feature selection, we applied different algorithms to find the most
accurate classification of the different stages/substages. A significantly smaller number of
features allowed us to use several classifiers and optimize their parameters. The classifiers
used for comparison include support vector machine (SVM) [26] with the radial basis func-
tion (RBF), linear and polynomial kernels, random forest [21], decision tree [22] and na¨ıve
Bayes.
Prostate cancer progression
To identify differentially expressed transcripts in prostate cancer progression, we formulated
the problem by following a multi-class supervised classification model. The samples were
grouped based on pairs of consecutive stages/sub-stages (T1c, T2, T2a, T2b, T2c, T3,
T3a, T3b and T4) as outlined in Table 4.4. To formulate the multi-class classification
problem, each sample contains the FPKM values for each transcript as features, and each
pair of consecutive stages/sub-stages serve as class labels. Since some stages, such as T3
and T4, contain a small number of samples, the ability of the classifier to retrieve the
discriminative power of the data would be reduced. In addition, the classifier may lose
generalization power, and hence may cause overfitting. Therefore, to compensate for this
imbalance, stage T3 samples were merged with T3a samples and stage T4 with T3b samples.
Furthermore, we combined stages T3, T3a, T3b, and T4 samples into a single group and
named it as T3/T4 to study the transcripts expression in the latter stages of progression
versus T2c. Reconstructing the transcriptome for all samples using Cuﬄinks resulted in
43,497 transcripts or features to be considered in the classification model. As this number is
prohibitive for a typical classification algorithm, we applied feature selection to reduce the
dimensionality of the problem, and to improve the performance of the model, while delivering
a set of meaningful transcripts as potential biomarkers. Transcripts were filtered following a
wrapper feature selection approach that uses mRMR. The classifier we used was SVM along
109
with the linear kernel with normalization. The wrapper feature selection algorithm was run
on the well-known data mining tool Weka [23]. Optimizing the parameters of the SVM in
the wrapper-based approach for feature selection on 43,497 transcripts would be a daunting
task. Thus, the linear SVM was selected as the wrapper method because it yields accurate
and fast classification, while using default parameters.
5.3 Results
Using the proposed model, we conducted two different experiments: First, on malignant
tumors versus their matched normal counterparts and, second, on samples from various
stages of prostate cancer progression.
5.3.1 Malignant versus matched normal comparison
We tested and validated our proposed wrapper-based feature-selection method on three
different datasets (Kannan’s, Kim’s and Ren’s datasets). Table 5.3 and Figure 5.2 show the
differentially expressed transcripts (i.e., malignant versus normal) identified in each dataset.
Two of the identified transcripts (NM 019024 and NM 001242889; corresponding to genes
HEATR5B and DDC, respectively) were common between Kannan’s and Kim’s datasets,
whereas one identified transcript (NR 024490; corresponding to the gene GABPB1− A51)
was common between both Kim’s and Ren’s datasets.
Figure 5.3 shows the average of transcript abundance for malignant versus matched normal
samples. The bars represent mean FPKM values for the three common transcripts selected.
The averages of FPKM values were calculated for both malignant and matched normal
samples in the three datasets in such a way that the result of each dataset are comparable on
an uneven field. Transcript NM 001242889 (DDC) was found to be differentially expressed in
malignant samples compared to matched normal samples. DDC has previously been shown
to be over-expressed in cancer samples compared to their matched normal samples. Similar
patterns were observed in our results, which suggests that DDC gene is a relevant biomarker
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for prostate cancer.
Figure 5.4 shows the performance of five different classifiers on discriminating malignant
samples from their matched normal counterparts in the three datasets. The classifiers were
Figure 5.2: Genes corresponding to the differentially expressed transcripts identified in Kannan’s, Kim’s and
Ren’s datasets.
Figure 5.3: Expression trend of matched normal versus malignant transcripts.
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trained with default parameters and validated via the 10-fold cross validation approach.
We used accuracy (ACC) and area under ROC curve (AUC) to evaluate the performance
of the classifiers, which show that the SVM classifier with a linear kernel outperformed all
other classifiers for the three datasets. These classification results show that using a handful
of transcripts – less than ten for each dataset – malignant tumors can be easily identified
with almost perfect accuracy, in most cases. This has an important implication in clinical
contexts, by virtue of the fact that effective and simple tools for diagnosis and prognosis of
the disease can be developed.
The results of applying mRMR feature selection to identify the top discriminative tran-
scripts between pairs of consecutive stages was compared to the results obtained after ap-
plying CuffDiff [6], a tool that uses statistical methods to identify differentially expressed
transcripts. In each pair of consecutive stages, the proposed model identified fewer selected
Table 5.3: Differentially expressed transcripts identified in Kannan’s, Kim’s and Ren’s datasets.
Dataset Transcript ID Transcript
Type
Gene Name Description
Kannan
[10]
NM 019024 mRNA HEATR5B HEAT repeat containing 5B
NM 001242889 mRNA DDC Dopa decarboxylase, tran-
script variant 6
NM 152228 mRNA TAS1R3 Taste 1 receptor member 3
NM 001204401 mRNA XIAP X-linked inhibitor of apopto-
sis, transcript variant 2,
Kim
[17]
NR 024490 LncRNA GABPB1-AS1 GABPB1 antisense RNA 1
NM 001242889 mRNA DDC Dopa decarboxylase, tran-
script variant 6
Nm 019024 mRNA HEATR5B HEAT repeat containing 5B
NM 032415 mRNA CARD11 caspase recruitment domain
family member 11, transcript
variant 2
Ren
[13]
NR 024490 LncRNA GABPB1-AS1 GABPB1 antisense RNA 1
NM 000424 mRNA KRT5 Keratin 5
NM 001128826 mRNA NCS1 Neuronal calcium sensor 1,
transcript variant 2
NM 000494 mRNA COL17A1 Collagen type XVII alpha 1
chain
NM 000700 mRNA ANXA1 Annexin A1
NM 005567 mRNA LGALS3BP Galectin 3 binding protein
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transcripts as compared to the CuffDiff model (Table 11). We evaluated the performance of
the two aforementioned models using different performance measures that include Accuracy
(ACC), F-measure (FM), Matthews correlation coefficient (MCC) and Area under curve
AUC. For classification, we used the cost sensitive meta-classifier model along with random
forest classifier (100 trees) with the same settings for both models. In each case, we obtained
a much higher performance using transcripts selected from our feature-selection method
rather than that of CuffDiff. Importantly, we observed no overlap between transcripts de-
tected by the two models, stressing the importance of the new method for isolating hits as
biomarkers for progression of prostate cancer. Table 5- Top transcripts that discriminate
stages T2 and T2A of prostate cancer
Figures 5-11 depict transcripts listed in Tables 4-10, respectively, across different stages
Figure 5.4: Performance of five different classifiers for matched normal versus malignant classification.
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of prostate cancer. The x-axis shows the stages of prostate cancer, while the y-axis shows
the median of FPKM values of samples in each stage. Of particular interest are transcripts
that are significantly altered at the critical transition from stage T2 to T3/T4 (Figures 9
Table 5.4: Top transcripts that discriminate stages T2 and T2A of prostate cancer.
Transcript Chr. Type Description Gene
NM 004860 17 mRNA Fragile X mental retardation, auto-
somal homolog 2
FXR2
NM 052850 19 mRNA Growth arrest and DNA damage-
inducible, gamma interacting pro-
tein 1
GADD45GIP1
NM 001272095 16 mRNA Syntaxin 4, transcript variant 1 STX4
NM 001261390 17 mRNA Calcium binding and coiled-coil do-
main 2, transcript variant 1
CALCOCO2
NM 153274 1 mRNA Bestrophin 4 BEST4
NM 001252641 19 mRNA Prefoldin-like chaperone, tran-
script variant 3
URI1
NR 038352 5 ncRNA Decapping mRNA 2, transcript
variant 3
DCP2
Table 5.5: Top transcripts that discriminate stages T2A and T2B of prostate cancer.
Transcript Chr. Type Description Gene
NM 032023 10 mRNA Ras association (RalGDS/AF-6) do-
main family member 4
RASSF4
NM 080792 20 mRNA Signal-regulatory protein alpha
(SIRPA), transcript variant 3
SIRPA
NM 000095 19 mRNA Cartilage oligomeric matrix protein COMP
NM 003102 4 mRNA Superoxide dismutase 3, extracellular SOD3
NM 080797 20 mRNA Death inducer-obliterator 1, transcript
variant 3
DIDO1
NM 002725 1 mRNA Proline/arginine-rich end leucine-rich
repeat protein, transcript variant 1
PRELP
Table 5.6: Top transcripts that discriminate stages T2B and T2C of prostate cancer.
Transcript Chr. Type Description Gene
NM 001711 X mRNA Homo sapiens biglycan BGN
NM 032023 10 mRNA Ras association (RalGDS/AF-6) do-
main family member 4
RASSF4
NM 001014443 1 mRNA Ubiquitin specific peptidase 21, tran-
script variant 3
USP21
NM 021724 17 mRNA Nuclear receptor subfamily 1, group
D, member 1
NR1D1
NM 012098 9 mRNA Angiopoietin-like 2 ANGPTL2
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and 11). DOCK9 (Figure 9) and FLVCR2 IK2F3, USP13, PTGFR, CLASP1 (Figure 11)
are all transcripts that significantly increase at the T2 transition and remain elevated in ad-
vanced prostate cancer stages. These may represent novel indicators – either individually or
combined as a signature. They may also represent novel targets for therapeutic intervention.
5.4 Conclusion and discussion
Identifying novel biomarkers to clearly distinguish between low and high-risk prostate cancer
progression is a very important step toward directing treatment strategies that are efficacious
yet minimally invasive. Using the power of next generation sequencing technologies and
machine learning techniques, we found several transcripts that have the potential to serve as
prognostic indicators in guiding treatment decisions. These transcripts constitute a genomic
and transcriptomic signature of prostate cancer and its progression, which has never been
Table 5.7: Top transcripts that discriminate stages T2C and T3A of prostate cancer.
Transcript Chr. Type Description Gene
NM 001198979 1 mRNA Small ArfGAP2 (SMAP2), tran-
script variant 2
SMAP2
NM 001099285 2 mRNA Prothymosin, alpha (PTMA), tran-
script variant
1
TMSA
NM 001198899 1 mRNA YY1 associated protein 1
(YY1AP1), transcript variant
6
YY1AP1
NM 001130048 13 mRNA Dedicator of cytokinesis 9 (DOCK9),
transcript variant 2
DOCK9
NM 000899 12 mRNA KIT ligand (KITLG), transcript
variant b
KITLG
Table 5.8: Top transcripts that discriminate stages T3A and T3B of prostate cancer.
Transcript Chr. Type Description Gene
NR 034169 2 ncRNA Family with sequence similarity 133,
member D
FAM133DP
NM 015380 22 mRNA SAMM50 sorting and assembly ma-
chinery component
SAMM50
NR 046417 15 ncRNA Olfactory receptor, family 4,
subfamily F, member 13,
pseudogene
OR4F13P
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characterized before. Further studies using wet-lab experiments and clinical assays will
be important to confirm the presence of these indicators in particular biological processes
involved in the disease and its progression. Some of our isolated genes have previously been
linked to other forms of cancer. For example, NREP (P311) is a transcript upregulated
in stages T3 to T4 as compared to T2c. Although there are no published reports on the
role of NREP on prostate cancer, it has been shown to be involved in glioma motility
and invasion via the reorganization of the actin cytoskeleton at the periphery of these cells
[24]. Upregulation of NREP expression from stages T3 to T4 is consistent with invasion of
prostate cancer cells extending beyond the prostatic capsule during this stage. Our results
also revealed upregulation of the gene expression of the small Cajal body-specific RNA
(scaRNA22) from stages T2c to T3/T4. scaRNA22 is a non-coding RNA involved in the
maturation of other RNA molecules, and along with other small nucleolar RNA, has been
Table 5.9: Top transcripts that discriminate stages T2C and T3/T4 of prostate cancer.
Transcript Chr. Type Description Gene
NM 001257413 17 mRNA IKAROS family zinc finger 3 (Aio-
los) , transcript variant 12
IKZF3
NM 003940 3 mRNA Ubiquitin specific peptidase 13
(isopeptidase T-3)
USP13
NM 001142274 2 mRNA Cytoplasmic linker associated pro-
tein 1, transcript
variant 3
CLASP1
NM 001199165 17 mRNA Centrosomal protein 112kDa, tran-
script variant 3
CEP112
NM 052965 1 mRNA tRNA splicing endonuclease subunit,
transcript variant 1
TSEN15
NM 001195283 14 mRNA Feline leukemia virus subgroup C cel-
lular receptor. family, member 2,
transcript variant 2
FLVCR2
NM 001023567 15 mRNA Golgin A8 family, member B, tran-
script variant 1
GOLGA8B
NM 001143766 10 mRNA Zinc finger protein 438, transcript
variant 1
ZNF438
NR 003004 4 snoRNA Small Cajal body-specific RNA 22 SCARNA22
NM 017753 9 mRNA Lipid phosphate phosphatase-related
protein. type 1, transcript variant 2
LPPR1
NM 000959 1 mRNA Prostaglandin F receptor (FP), tran-
script variant 1
PTGFR
NM 004772 5 mRNA Neuronal regeneration related pro-
tein, transcript variant 1
NREP
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linked to human cancers [25]. Typically located in the introns of host genes, upregulation
of scaRNA22 was found in multiple myeloma harboring chromosomal translocations and
may suppress oxidative stress, facilitate cell proliferation and protect cells from the effects
of chemotherapy [26]. Our study is the first to link scaRNA22 with prostate cancer and
progression of the disease.
In particular, we have isolated a set of transcripts that are significantly altered at the
critical transition between stages T2 and T3/4 and remain elevated. These are transcripts
from the genes DOCK9, FLVCR2, IK2F3, USP13, PTGFR and CLASP1. In the human
protein atlas, Dock9, Clasp1 and USP13 protein levels are highly expressed in prostate
cancer tissues. Dock9 is a Rho GEF responsible for activating Rho-GTPases and known to
be implicated in tumorigenesis [27, 28]. While the protein atlas has not detected PTGFR
Table 5.10: Comparison between CuffDiff and our feature-selection method for identifying differentially
expressed transcripts between each pair of consecutive stages of prostate cancer.
Stage Method # se-
lected
Tran-
scripts
# Com-
mon
Tran-
scripts
ACC FM MCC AUC
T1C-T2
(14 vs 10)
CuffDiff 21 0 70.8% 0.710 0.410 0.846
Proposed Method 6 95.8% 0.958 0.917 0.971
T2-T2A
(10 vs 23)
CuffDiff 43 0 69.7% 0.650 0.159 0.580
Proposed Method 7 93.9% 0.939 0.857 0.970
T2A-T2B
(23 vs 11)
CuffDiff 35 0 64.7% 0.601 0.068 0.634
Proposed Method 6 85.3% 0.851 0.657 0.826
T2B-T2C
(11 vs 30)
CuffDiff 38 0 65.8% 0.647 0.078 0.645
Proposed Method 5 87.8% 0.880 0.699 0.885
T2C-T3A
(30 vs 8)
CuffDiff 29 0 73.7% 0.722 0.130 0.612
Proposed Method 5 89.4% 0.895 0.683 0.948
T3A-T3B
(8 vs 9)
CuffDiff 27 0 58.8% 0.588 0.181 0.750
Proposed Method 3 94.1% 0.941 0.887 1.000
T2C-
T3/T4
(30 vs 17)
CuffDiff 49 0 57.4% 0.568 0.055 0.483
Proposed Method 12 95.7% 0.957 0.908 0.988
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as highly stained in prostate cancer, gene expression of PTGFR is associated with cell
proliferation and in vivo progression to castration-recurrent prostate cancer, an end stage
of the disease [29]. In ovarian cancer, overexpression of PTGFR stimulates the spontaneous
development and secretion of autoantibodies against the protein, as detected in the sera
of cancer patients [30]. Autoantibodies against PTGFR may serve as biomarkers for early
serological detection of the disease. Overexpression of PTGFR has also been reported in
human tumor-endothelial cells of renal cell carcinoma where it is believed to be involved in
tumor angiogenesis [31]. Whether these transcripts, or their protein products, can be used
alone or in combination as a prognostic indicator for prostate cancer is an important next
step of this work. It is also interesting to consider that these protein products may represent
novel drug targets for advanced disease.
Figure 5.5: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T1c and T2.
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Figure 5.6: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2 and T2a.
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Figure 5.7: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2a and T2b.
Figure 5.8: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2b and T2c.
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Figure 5.9: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2c and T3a.
Figure 5.10: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T3a and T3b.
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Figure 5.11: Stage-specific expression level of transcripts that have been selected based on their significant
expression changes between stages T2c and T3/T4.
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Chapter 6
Conclusion and future work
6.1 Conclusion
The main contribution of this thesis is to provide a generic pipeline for modeling RNA-
Seq data as a supervised or non supervised learning scheme used to obtain meaningful
biomarkers in cancer. Starting from preprocessing RNA-Seq data to model the different
cancer problems, the proposed model showed high performance and throughput. Via this
model we were able to extract transcriptomic biomarkers that are strongly related to prostate
cancer, breast cancer and other types of cancers. Additionally, we have performed biological
validation using the literature and in collaboration with biologists to investigate the obtained
biomarkers using wet-lab experiments, such as what has been done for CAMK2G in Chapter
3. We were also able to identify some other biomarkers such as a novel transcripts for WW2
genes, while processing the data set from Chinese populations. Our biologist collaborators
deeply investigated WW2 and found that the novel transcript can double the gene expression
in the cancer cell lines [1].
The main methods of this work were able to handle different machine learning problems
such as the curse of dimensionality and narrowing down the number of biomarker genes to
a few of them, in order to furhter analyze them. We also solved the problem of data sets
with imbalanced classes (in which the standard classifiers are biased towards the majority
class) as in Chapter 4 models, and we were able to detect the harmful minor miRNA from
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Table 6.1: List of biomarkers that have been extracted by our methods
Biomarker Transcriptomic type Cancer problem
WWP2 novel transcript prostate progression
STMN1 transcript NM005563 prostate progression
CAMK2G transcript NM001222 prostate progression
RUNX3 transcript NM004350 prostate progression
MSMB transcript NM002443 prostate progression
PLA2G2A transcript NM001161728 prostate progression
AGR2 Gene expression Breast cancer subtype - Basel
TFF3 Gene expression Breast cancer subtype - Basel
YBX1 Gene expression Breast cancer subtype - Her2
CX3CL1 Gene expression Breast cancer subtype - Normal
BUB1 Gene expression Breast cancer subtype - LumA
COX4NB Gene expression Breast cancer subtype - LumB
PSAP Gene expression Breast cancer time-series Outlier (survival-treatment)
SCGB2A2 Gene expression Breast cancer time-series Outlier - oncogene
the majority of other non-coding RNA [2]. As an initial step of this work, we have tried
different machine learning models to cluster transcriptomic profiles in order to find patterns
from time-series data [3]. In this thesis, we did not only apply well-known machine learning
approaches to analyze RNA-Seq cancer data, but we also created our own methods to handle
different machine learning problems.
In a nutshell, the contributions in this work can be summarized as follows.
• Proposing a new method for preprocessing RNA-Seq data used to remove low-complex
and highly-biased sequences from sequence reads.
• Modeling the cancer development (growth) using real data that have been taken from
different patients with different Cancer stages.
• Creating genomic and transcriptomic profiles with read quantifications on different time
series points (cancer stages) by interpolating the development of the profiles using cubic-
spline.
• Devising a machine learning model based on hierarchal clustering for finding outliers
from time-series data.
• Handling the multi-class problem using the one-versus-next approach for prostate cancer
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stages, and the one-versus-rest approach for breast cancer survivability treatments and
breast cancer subtype analysis.
• Finding biomarkers from time-series profiles, which follow different trends different than
the majority of the transcripts (background).
• Enhancing the generic hierarchical clustering method to detect both global and local
outliers.
Most parts of this work have been published in conferences in collaborations with my lab
mates, who have jointly co-authored these publications. Chapter 2, Zseq the preprocessing
tool for RNA-Seq data, has been published as a journal article, while the rest is either being
under review or going to be extended as journal articles which are in preparation.
6.2 Future work
Although we have proposed and developed powerful approaches for dealing with RNA-Seq
data, finding meaningful biomarkers and modelling cancer, there is some room for improve-
ment. The future work and extensions of this work are divided into two areas: biomarkers
and the underlying methods. For the biomarkers, we can further analyze, biologically, the
obtained biomarkers using different types of pathway analysis and wet-lab experiments that
are related to each cancer type or stage. For the hierarchical clustering method, we can fur-
ther automate the PAAC index using multi-objective optimization methods, such as Pareto
optimization [4].
Another future avenue to this work is to create an integrative approach that reads from
different sources of data for a specific type of cancer such as gene expression, RNA-Seq, CNA,
CNV, mutations and build a deep learning model that can learn from those different sources
and analyze the causes, treatments, and survivability chances of cancer based on specific
treatments. The pipeline resulting from this work can be integrated with a tool which we have
already started work on to find protein isoforms in the transcriptomic profiles [5]. Once we
extract the protein isoforms from RNA-Seq data, we can target protein-protein interactions
130
with drugs obtained from databases such as DrugBank [6] to study the most effective path of
treatment. The mutations in the RNA-Seq data can help us develop personalized medicine
approaches by checking whether a person mutation happens in a specific enzyme that may
effect the drug metabolism, which it may speed it up, slow it down, or shut down the whole
metabolism [7], which may lead to different responses from one patient to another due to
mutations or other genomic changes.
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Appendix A
Clustering time-series profiles using
wavelet based probability density
functions (PDF) for identifying
patterns in time series
A.1 The proposed clustering method
In this section, the proposed clustering method based on the combination of the probability
density function and hierarchical method is introduced. For this purpose, a wavelet based
probability density function is introduced to estimate a mixture of the PDF for each feature.
Then, “multi-level” thresholding is implemented to the PDF of the feature to cluster dataset.
After this stage, forward feature selection with memory is utilized to combine the features
and to maximize the number of the clusters. The PAAC index is considered for evaluating
the number of clusters and features.
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A.1.1 Wavelet-based density function estimation
The probability density function of each feature is estimated by wavelet basis function [1,2].
The orthogonal basis functions of the wavelets along with their localized properties provide
an accurate estimation of the PDF. In this method, a particular shape is not contended for
the PDF and let the data, itself, determine the shape of the PDF. For this purpose, suppose
that the data of feature x is available as (x(t), 1 ≤ t ≤ n), the density function of feature
x is unknown. The aim is to predict this density function, h(x), via the multi resolution
analysis introduced by Mallat [4]. For this aim, h(x) is considered as a linear combination
of scaling functions and its orthogonal wavelets as follows:
h (x) =
+∞∑
k=−∞
a0,kΦ0,k (x) +
0∑
m=−∞
+∞∑
k=−∞
dm,kΨm,k (x) (A.1)
Φm,k (x) = 2
−m
2 Φ
(
2−mx− k) ,m, k ∈ Z (A.2)
Ψm,k (x) = 2
−m
2
(
2−mx− k) ,m, k ∈ Z (A.3)
Where Φm,k (x) and Ψm,k (x) are scaling functions and their orthogonal wavelets, and m and,
k are dilation and translation factors of the scaling functions and the wavelets, respectively.
Furthermore, 2
−m
2 is used as an energy normalization factor. a0,kand dm,kare computed as
follows:
a0,k = h, Φ0,k > = ∫ Φ0,k (x) h (x) dx (A.4)
dm,k = h, Ψm,k >= ∫ Ψm,k (x) h (x) dx (A.5)
It must be noted that h(x) is not available, and a0,kand dm,kcannot be achieved by Eqs. (4)
and (5). Fortunately, h (x) is a density function, and hence ∫ Φ0,k (x)h (x) dxis equal to the
expectation of Φ0,k (x)and ∫ Ψm,k (x)h (x) dxis equal to the expectation of Ψm,k (x)Thus,
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a0,kand dm,kcan be formulated as follows:
a0,k = ∫ Φ0,k (x) h (x) dx = E (Φ0,k (x)) = 1
n
n∑
t=1
Φ0,k (x (t)) (A.6)
dm,k = ∫ Ψm,k (x) h (x) dx = E (Ψm,k (x)) = 1
n
n∑
t=1
Ψm,k (x (t)) (A.7)
It should be noted that the PDF obtained by Eqs (1), (6) and (7) are not smooth. There are
many methods for smoothing of the suggested PDF in the literature such as soft-thresholding
and hard-thresholding [1, 2].
A.1.2 The multi-level thresholding method
This subsection briefly illustrates multi-level thresholding method for clustering each feature
based on its PDF. Optimal multi thresholding is an important task in pattern recognition.
Rueda introduces a polynomial-time method for multilevel thresholding of irregularly sam-
pled histograms based on dynamic programming. The algorithm is polynomial not only
on the number of bins of the histogram, n, but also on the number of thresholds, k. The
algorithm can be generally applied for a wide range of thresholding and clustering criteria,
and it can be able to deal with irregularly sampled histograms. Furthermore, the algorithm
can determine the optimal thresholds in a fraction of a second. It should be noted that the
worst-case time complexity of the algorithm is θ
(
kn2
)
[3].
A.1.3 Forward feature selection with memory
In this subsection, a forward feature selection (floating search method) is presented [5, 6] to
merge the features and to provide the maximum number of the clusters. The forward feature
section algorithm engages starting with no features in the model, then, it tests adding of
each feature using a model comparison criterion, adding the feature if the feature improves
the model criterion. The algorithm repeats the process until no improvement in the model.
However, the algorithm is greedy and it is not optimal. To improve the performance of the
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method, the algorithm is considered with a memory known as the floating search method.
In the floating search method, the algorithm keeps the best feature and the second best
feature (memory) at each step. Although, the algorithm is still greedy and not optimal, but
it improves the performance of the method and it can be suboptimal.
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Appendix B
The clinical and sequencing details of
the Chinese prostate cancer dataset
All the sequencing runs for the dataset samples shares the following features: ethnic group
= Chinese, sex = male, Organism = Homo sapiens, disease = prostate carcinoma, Organism
part = prostate gland, Protocol REF = P-MTAB-33294, Library source = Transcriptomic,
Direction = Forward, Library layout = paired, Library selection = cDNA, Orientation =
5’-3’-5’-3’, Nominal length = 200bp, Performer = BGI, Technology type = sequencing assay.
While they have the following different features as seen in Table B.1:
Table B.1: The details of the samples sequencing runs
for the Chinese dataset.
Source
Name
Patient
id
age sampling
site
Extract
Name
Assay
Name
ENA RUN FactorValue
sampling
site
10N 10 75 adjacent
non-tumor
tissue
10N 10N 1 ERR031017 adjacent
non-tumor
tissue
139
10N 10 75 adjacent
non-tumor
tissue
10N 10N 2 ERR031017 adjacent
non-tumor
tissue
10T 10 75 tumor tis-
sue
10T 10T 1 ERR031018 tumor tis-
sue
10T 10 75 tumor tis-
sue
10T 10T 2 ERR031018 tumor tis-
sue
11N 11 57 adjacent
non-tumor
tissue
11N 11N 1 ERR031019 adjacent
non-tumor
tissue
11N 11 57 adjacent
non-tumor
tissue
11N 11N 2 ERR031019 adjacent
non-tumor
tissue
11T 11 57 tumor tis-
sue
11T 11T 1 ERR299295 tumor tis-
sue
11T 11 57 tumor tis-
sue
11T 11T 2 ERR299295 tumor tis-
sue
12N 12 80 adjacent
non-tumor
tissue
12N 12N 1 ERR299296 adjacent
non-tumor
tissue
12N 12 80 adjacent
non-tumor
tissue
12N 12N 2 ERR299296 adjacent
non-tumor
tissue
12T 12 80 tumor tis-
sue
12T 12T 1 ERR031022 tumor tis-
sue
12T 12 80 tumor tis-
sue
12T 12T 2 ERR031022 tumor tis-
sue
140
13N 13 75 adjacent
non-tumor
tissue
13N 13N 1 ERR031023 adjacent
non-tumor
tissue
13N 13 75 adjacent
non-tumor
tissue
13N 13N 2 ERR031023 adjacent
non-tumor
tissue
13T 13 75 tumor tis-
sue
13T 13T 1 ERR031024 tumor tis-
sue
13T 13 75 tumor tis-
sue
13T 13T 2 ERR031024 tumor tis-
sue
14N 14 73 adjacent
non-tumor
tissue
14N 14N 1 ERR031025 adjacent
non-tumor
tissue
14N 14 73 adjacent
non-tumor
tissue
14N 14N 2 ERR031025 adjacent
non-tumor
tissue
14T 14 73 tumor tis-
sue
14T 14T 1 ERR031026 tumor tis-
sue
14T 14 73 tumor tis-
sue
14T 14T 2 ERR031026 tumor tis-
sue
1N 1 74 adjacent
non-tumor
tissue
1N 1N 1 ERR031027 adjacent
non-tumor
tissue
1N 1 74 adjacent
non-tumor
tissue
1N 1N 2 ERR031027 adjacent
non-tumor
tissue
141
1T 1 74 tumor tis-
sue
1T 1T 1 ERR031028 tumor tis-
sue
1T 1 74 tumor tis-
sue
1T 1T 2 ERR031028 tumor tis-
sue
2N 2 73 adjacent
non-tumor
tissue
2N 2N 1 ERR031029 adjacent
non-tumor
tissue
2N 2 73 adjacent
non-tumor
tissue
2N 2N 2 ERR031029 adjacent
non-tumor
tissue
2T 2 73 tumor tis-
sue
2T 2T 1 ERR031030 tumor tis-
sue
2T 2 73 tumor tis-
sue
2T 2T 2 ERR031030 tumor tis-
sue
3N 3 71 adjacent
non-tumor
tissue
3N 3N 1 ERR031031 adjacent
non-tumor
tissue
3N 3 71 adjacent
non-tumor
tissue
3N 3N 2 ERR031031 adjacent
non-tumor
tissue
3T 3 71 tumor tis-
sue
3T 3T 1 ERR031032 tumor tis-
sue
3T 3 71 tumor tis-
sue
3T 3T 2 ERR031032 tumor tis-
sue
4N 4 54 adjacent
non-tumor
tissue
4N 4N 1 ERR031033 adjacent
non-tumor
tissue
142
4N 4 54 adjacent
non-tumor
tissue
4N 4N 2 ERR031033 adjacent
non-tumor
tissue
4T 4 54 tumor tis-
sue
4T 4T 1 ERR299297 tumor tis-
sue
4T 4 54 tumor tis-
sue
4T 4T 2 ERR299297 tumor tis-
sue
5N 5 62 adjacent
non-tumor
tissue
5N 5N 1 ERR031035 adjacent
non-tumor
tissue
5N 5 62 adjacent
non-tumor
tissue
5N 5N 2 ERR031035 adjacent
non-tumor
tissue
5T 5 62 tumor tis-
sue
5T 5T 1 ERR299298 tumor tis-
sue
5T 5 62 tumor tis-
sue
5T 5T 2 ERR299298 tumor tis-
sue
6N 6 69 adjacent
non-tumor
tissue
6N 6N 1 ERR299299 adjacent
non-tumor
tissue
6N 6 69 adjacent
non-tumor
tissue
6N 6N 2 ERR299299 adjacent
non-tumor
tissue
6T 6 69 tumor tis-
sue
6T 6T 1 ERR031038 tumor tis-
sue
6T 6 69 tumor tis-
sue
6T 6T 2 ERR031038 tumor tis-
sue
143
7N 7 52 adjacent
non-tumor
tissue
7N 7N 1 ERR031039 adjacent
non-tumor
tissue
7N 7 52 adjacent
non-tumor
tissue
7N 7N 2 ERR031039 adjacent
non-tumor
tissue
7T 7 52 tumor tis-
sue
7T 7T 1 ERR031040 tumor tis-
sue
7T 7 52 tumor tis-
sue
7T 7T 2 ERR031040 tumor tis-
sue
8N 8 66 adjacent
non-tumor
tissue
8N 8N 1 ERR031041 adjacent
non-tumor
tissue
8N 8 66 adjacent
non-tumor
tissue
8N 8N 2 ERR031041 adjacent
non-tumor
tissue
8T 8 66 tumor tis-
sue
8T 8T 1 ERR031042 tumor tis-
sue
8T 8 66 tumor tis-
sue
8T 8T 2 ERR031042 tumor tis-
sue
9N 9 56 adjacent
non-tumor
tissue
9N 9N 1 ERR031043 adjacent
non-tumor
tissue
9N 9 56 adjacent
non-tumor
tissue
9N 9N 2 ERR031043 adjacent
non-tumor
tissue
144
9T 9 56 tumor tis-
sue
9T 9T 1 ERR031044 tumor tis-
sue
9T 9 56 tumor tis-
sue
9T 9T 2 ERR031044 tumor tis-
sue
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Appendix C
The clinical and sequencing details of
the North American prostate cancer
dataset
Table C.1: The clinical and sequencing information of
the samples from the North American dataset.
CGSR ID External
ID
Study
ID
no. of
uniquely
mapped
reads
%
mapped
reads
Gleason
Score
age race pStage
PT081 MCC-
PT081
MCC-
PT081
251,516,583 63.0% 347 78.0 W pT3
PT127 MCC-
PT127
MCC-
PT127
9,995,053 65.8% 336 61.0 W pT2
PT168 MCC-
PT168
MCC-
PT168
10,476,268 64.6% 336 63.0 W pT2
146
PT184 MCC-
PT184
MCC-
PT184
20,241,959 67.0% 347 58.0 NA pT3
PT199 MCC-
PT199
MCC-
PT199
13,030,802 64.4% 347 57.0 W pT2
PT236 MCC-
PT236
MCC-
PT236
15,108,250 66.2% 347 54.0 W pT2
PT243 MCC-
PT243
MCC-
PT243
20,783,424 62.1% 347 43.0 NA pT2
UTPC008 UTPC008 UTPC008 101,038,395 69.0% 437 57.0 NA pT1C
UTPC020 UTPC020 UTPC020 48,519,295 56.9% 448 66.0 NA pT2B
UTPC107 UTPC107 UTPC107 60,698,177 62.7% 336 50.0 NA pT1C
CM.1-
0028.1
UTPC162 UTPC162 16,673,391 63.8% 347 69.0 NA pT1C
CM.4-0087 VA-PC-
00-87
00LH1 58,978,596 72.9% 347 68.8 B pT2C
CM.4-0090 VA-PC-
00-90
00JC1 26,387,543 46.5% 347 55.6 B pT2
CM.4-0091 VA-PC-
00-91
00AS1 29,052,523 66.4% 437 62.1 W pT2C
CM.4-0092 VA-PC-
00-92
00ES1 53,860,194 70.5% 538 63.1 B pT3A
CM.4-0093 VA-PC-
00-93
00CH1 95,708,411 80.0% 347 52.5 W pT2A
CM.4-0094 VA-PC-
00-94
00JB1 49,844,364 69.1% 347 62.4 B pT3A
CM.4-0095 VA-PC-
00-95
00HA1 59,522,602 66.1% 347 69.0 B pT2C
147
CM.4-0097 VA-PC-
00-97
00JJ2 81,114,085 77.0% 336 51.4 W pT2C
CM.4-0098 VA-PC-
00-98
00JM1 30,149,534 72.0% 347 68.4 W pT2C
CM.4-0061 VA-PC-
91-61
91HH1 39,377,172 49.7% 437 56.6 W pT2C
CM.4-0062 VA-PC-
91-62
91EM1 58,589,794 62.9% 448 63.8 W pT2C
CM.4-0064 VA-PC-
91-64
91HL1 50,897,494 79.9% 347 69.1 W pT2C
CM.4-0013 VA-PC-
92-13
92GG1 9,199,337 68.4% 347 64.9 W pT2A
CM.4-0014 VA-PC-
92-14
92WM1 58,111,320 46.9% 347 70.2 W pT2C
CM.4-0066 VA-PC-
92-66
92LS1 42,010,928 47.7% 347 65.1 W pT2
CM.4-0067 VA-PC-
92-67
92PG1 42,716,254 60.1% 347 66.6 W pT2
CM.4-0019 VA-PC-
93-19
93RS1 21,723,177 80.1% 347 64.1 W pT2A
CM.4-0068 VA-PC-
93-68
93CA1 50,028,024 70.6% 437 61.3 W pT2C
CM.4-0028 VA-PC-
94-28
94CD1 82,057,308 69.9% 347 56.3 B pT2C
CM.4-0070 VA-PC-
94-70
94JL1 66,648,540 72.5% 347 69.6 B pT3A
148
CM.4-0045 VA-PC-
96-45
96HH1 39,787,464 64.1% 347 50.4 W pT3A
CM.4-0047 VA-PC-
97-47
97RM1 16,010,891 19.6% 347 53.7 W pT2C
CM.4-0048 VA-PC-
97-48
97EC1 39,114,735 59.9% 347 50.0 B pT2C
CM.4-0049 VA-PC-
97-49
97WT1 38,014,897 45.3% 336 64.2 W pT2A
CM.4-0050 VA-PC-
97-50
97JS1 42,286,269 47.8% 347 60.5 W pT2A
CM.4-0051 VA-PC-
97-51
97FH1 21,954,686 29.3% 437 57.3 B pT2B
CM.4-0052 VA-PC-
97-52
97DS1 14,877,664 14.9% 437 64.0 W pT2C
CM.4-0074 VA-PC-
97-74
97RS1 96,287,979 66.6% 347 72.4 W pT2C
CM.4-0054 VA-PC-
99-54
99RE1 49,857,683 69.8% 437 59.0 W pT2A
CM.4-0055 VA-PC-
99-55
99BE1 47,695,326 51.2% 347 47.2 B pT2C
CM.4-0075 VA-PC-
99-75
99WW1 91,549,024 48.7% 347 54.4 W pT2A
CM.4-0076 VA-PC-
99-76
99TD1 45,313,892 55.0% 347 54.7 W pT2C
CM.4-0077 VA-PC-
99-77
99AS1 32,490,259 75.1% 336 55.9 B pT2A
149
CM.4-0078 VA-PC-
99-78
99DH1 64,869,418 75.3% 347 62.4 B pT2A
CM.4-0079 VA-PC-
99-79
99CT1 31,069,486 78.4% 347 64.8 W pT2B
CM.4-0080 VA-PC-
99-80
99LH1 82,407,763 60.0% 347 54.4 B pT2C
CM.4-0081 VA-PC-
99-81
99LW1 32,471,983 70.7% 437 65.6 W pT2
CM.4-0082 VA-PC-
99-82
99CC1 65,045,734 55.0% 347 62.5 W pT2C
CM.4-0083 VA-PC-
99-83
99WM1 52,536,474 62.6% 347 50.4 B pT2A
CM.4-0084 VA-PC-
99-84
99RR1 24,586,944 59.1% 336 64.7 W pT2A
PT197 MCC-
PT197
83,866,689 60.9% 336 66.0 W pT1C
PT220 MCC-
PT220
72,366,520 43.2% 336 61.3 W pT1C
PT264 MCC-
PT264
71,163,980 54.0% 325 60.1 W NA
CM.1-
0001.1
UTPC004 UTPC4 73,667,210 58.9% 549 71.0 NA pT1C
UTPC004 UTPC004 UTPC004 94,148,591 61.6% 549 71.0 NA pT1C
CM.1-
0002.1
UTPC009 UTPC9 16,891,119 56.4% 347 50.0 NA pT2B
UTPC009 UTPC009 UTPC009 95,747,467 57.4% 347 50.0 NA pT2B
150
CM.1-
0003.1
UTPC019 UTPC19 59,982,964 54.8% 437 64.0 NA pT2A
UTPC019 UTPC019 UTPC019 52,303,635 55.1% 437 64.0 NA pT2A
CM.1-
0004.1
UTPC021 UTPC21 46,997,412 39.9% 437 68.0 NA pT1C
UTPC021 UTPC021 UTPC021 46,997,412 52.8% 437 68.0 NA pT1C
CM.1-
0005.1
UTPC029 UTPC29 65,468,819 57.2% 347 58.0 W pT2A
UTPC029 UTPC029 UTPC029 100,596,892 58.4% 347 58.0 NA pT2A
CM.1-
0006.1
UTPC034 UTPC34 18,135,372 41.3% 347 55.0 NA pT2B
UTPC034 UTPC034 UTPC034 111,754,397 62.1% 347 55.0 NA pT2B
UTPC041 UTPC041 UTPC041 95,370,297 63.5% 347 71.0 NA pT1C
CM.1-
0008.1
UTPC058 UTPC58 17,542,055 43.6% 347 65.0 NA pT2B
CM.1-
0012.1
UTPC088 UTPC88 25,814,843 60.8% 336 62.0 NA pT1C
CM.1-
0013.1
UTPC093 UTPC93 16,692,025 56.9% 347 58.0 NA pT2A
CM.1-
0015.1
UTPC099 UTPC99 13,757,579 55.5% 459 67.0 NA pT2B
CM.1-
0016.1
UTPC101 UTPC101 75,959,530 55.1% 448 70.0 NA pT3B
CM.1-
0017.1
UTPC104 UTPC104 75,764,019 58.9% 437 59.0 NA pT2A
CM.1-
0018.1
UTPC110 UTPC110 25,416,364 67.2% 549 53.0 NA pT2B
151
CM.1-
0019.1
UTPC114 UTPC114 64,266,720 63.6% 347 60.0 NA pT1C
CM.1-
0020.1
UTPC116 UTPC116 20,810,790 69.1% 347 60.0 NA pT2A
CM.1-
0021.1
UTPC127 UTPC127 86,871,782 63.9% 437 58.0 NA pT3B
CM.1-
0022.1
UTPC131 UTPC131 18,275,411 64.4% 437 51.0 NA pT3B
CM.1-
0023.1
UTPC132 UTPC132 31,782,258 47.8% 437 65.0 NA pT2A
CM.1-
0025.1
UTPC141 UTPC141 57,654,792 48.8% 347 74.0 NA pT2A
CM.1-
0026.1
UTPC146 UTPC146 34,232,839 49.8% 448 72.0 W pT3B
CM.1-
0027.1
UTPC147 UTPC147 17,789,548 60.1% 347 66.0 NA pT2A
UTPC160 UTPC160 UTPC160 32,943,917 28.2% 347 57.0 NA pT1C
UTPC164 UTPC164 UTPC164 123,211,885 61.2% 437 66.0 NA pT2A
CM.1-
0030.1
UTPC170 UTPC170 70,019,189 66.0% 437 72.0 NA pT1C
CM.4-0086 VA-PC-
00-86
00TW1 100,294,010 77.2% 437 59.6 B pT3B
CM.4-0088 VA-PC-
00-88
00JS1 94,922,445 68.3% 347 53.5 B pT2C
CM.4-0096 VA-PC-
00-96
00DF1 102,465,236 65.8% 437 58.4 W pT2C
152
CM.4-0099 VA-PC-
00-99
00AR1 67,659,170 74.6% 437 65.7 B pT3A
CM.4-0004 VA-PC-
90-4
90GD1 79,371,670 63.0% 448 59.0 NA pT3B
CM.4-0065 VA-PC-
91-65
91JP1 62,526,982 72.7% 459 55.0 B pT3B
CM.4-0011 VA-PC-
92-11
92AC1 91,714,533 61.8% 448 63.9 W pT3B
CM.4-0009 VA-PC-
92-9
92HM1 37,147,471 47.6% 347 67.4 W pT3B
CM.4-0020 VA-PC-
93-20
93JM1 74,903,758 75.2% 448 52.0 W pT2C
CM.4-0021 VA-PC-
93-21
93AS1 73,477,400 65.3% 347 66.5 W pT2C
CM.4-0024 VA-PC-
93-24
93FC1 34,139,269 44.8% 437 66.6 W pT2
CM.4-0071 VA-PC-
94-71
94JH1 59,808,026 74.4% 448 64.8 W pT2C
CM.4-0034 VA-PC-
95-34
95CM1 30,409,790 48.5% 347 62.0 W pT2C
CM.4-0037 VA-PC-
95-37
95BB1 50,090,466 62.3% 347 57.7 B pT2C
CM.4-0041 VA-PC-
95-41
95HD1 48,679,745 56.3% 347 58.0 B pT2C
CM.4-0042 VA-PC-
95-42
95CJ1 23,750,742 51.0% 347 66.8 W pT4
153
CM.4-0043 VA-PC-
96-43
96JL1 84,811,432 61.1% 437 61.8 W pT2C
CM.4-0044 VA-PC-
96-44
96DC1 70,792,590 62.0% 347 51.8 B pT2C
CM.4-0046 VA-PC-
97-46
97RC1 71,695,143 58.8% 437 58.6 W pT2C
CM.4-0053 VA-PC-
98-53
98RS2 85,477,421 66.9% 448 61.6 B pT2A
CM.4-0085 VA-PC-
99-85
99JH1 96,977,746 81.4% 347 56.9 W pT3A
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